annual report roche group annual report group accounts roche holding ltd basel annual accounts key figures millions chf roche group continuing businessesa change change local local cur cur chf rency chf rency sales ebitdab operating profit exceptional items operating profit net income research development additions property plant equipment personnel number employees december ratios ebitdabas sales operating profit exceptional items sales operating profit sales net income sales research development sales data shares nonvoting equity securities chf earnings per share nonvoting equity security diluted dividends per share nonvoting equity securityc continuing businesses includes core pharmaceuticals diagnostics businesses together treasury corporate activities vitamins fine chemicals division reported discontinuing business b ebitda earnings exceptional items interest financial income tax depreciation amortisa tion including impairment corresponds operating profit exceptional items depreciation andamortisation including impairment c dividend proposed board directorsgroup performance glance latot latot latot latot latot sales division millions chf pharmaceuticals diagnostics vitamins fine chemicals nonvoting equity security genussschein price performance chf roche nonvoting equity security adjusted swiss market index rebased figures adjusted basis figures continuing businesses operating profit exceptional items figures fully comparable due givaudan spinoff vitamins fine chemicals demerger genentech transactions accounting policy changes group figures net income millions chf net income per share ebitda millions chf nonvoting equity security chf operating profit millions chf research development millions chf additions property plant equipment millions chf roche group annual report group accounts roche holding ltd basel annual accounts table contents letter chairman board directors executive committee group performance group strategy divisions pharmaceuticals diagnostics corporate governance finance financial review roche group consolidated financial statements notes roche group consolidated financial statements report group auditors multiyear overview roche securities roche holding ltd basel financial statements notes financial statements appropriation available earnings report statutory auditors roche global market presence table contents goal improve peoples health quality life around world roche scientists working discover innovative highquality solutions unmet medical needsdoubledigit sales growth local currencies pharmaceuticals diagnostics increase market share profitability group operating profit grows faster sales net income back healthy level hepatitis c drug pegasys exceeds expectations pharma pipeline substantially improved expanded disetronic igen acquisitions boost strength diagnostics division improvements corporate governance groups first separate sustainability report documents broad commitment good corporate citizenship roche expects outpace market growth results exceptional itemsletter chairman dear shareholders roche group made significant strategicoperational financial progress pharmaceuticals diagnostics divisions recorded growth rates well ahead respective marketsand thistogether increases profitability strong research development pipelinesconfirms strategy focus innovation tracknet income back healthy leveland continued restructuring finances reducing group debt timewe enhanced corporate governancethe board directors propose dividend increase swiss francs per share nonvoting equity security annual general meeting shareholders approvedthis groups seventeenth dividend increase many years letter chairmanwe pleased report sales diagnostics division grew achieved ambitious goals twice fast global invitro sales ofour pharmaceuticals diagnostics market last yearposting diagnostics divisions showed dou healthy increase local curren bledigit increase local currenciesoperating profit exceptional items grew faster result excellent performance salesadvancing local curren core businesses measures cies swiss francs bil lion swiss francsnet income ofour implemented finance group core businesses reached billion considerably stronger swiss francsfollowing net loss last year core pharmaceuticals diag ciesdue difficult economic nostics divisions grew faster conditionshoweverthe division fell marketsales pharmaceu short ofits goal ofachieving double ticals division increased digit sales growthroche diagnostics local currencies billion swiss expanded market share francsthe integration ofchugai percentage point posting sales japan contributed excellent billion francsthe divisions performanceas growth ofour profitability showed another marked business new established increasewith operating profit roche productswhich outpaced margin exceptional items global marketroche expanded improving percentage points global leadership oncology dur performance driven pri ing company marily rapidly growing diabetes three anticancer products caremolecular diagnostics extend patient survivaland immunochemistry businesses already filed application mar keting approval ofa fourthavastin thanks success operat regulatory authorities ing activitiesebitda core united states europethe market businesses increased local rollout ofour new hepatitis c drug currencies swiss francs pegasys progressing well toanimpressive billion swiss despite substantially higher spending francs new drug launches among novel hivaids drug fuzeon finance made good progress many highly promising restructuring reducing group projects development pipeline debt last yearachieving reduction pharmaceuticals division contin billion swiss francswe also ued improve profitabilityincreasing improved risk profile ofour finan operating profit margin cial investments foreign exchange exceptional items transactionsthe share offinancial previous year assets held equities reduced plannedneverthelessthe financial letter chairman statements show net finan promising projects cera anemia improve presentation cial expense ofaround million mabtherarituxan mra results line international swiss francsmainly due continuing rheumatoid arthritis financial reporting standards ifrs high interest expenses enter final phase ofclinical devel improve comparability opment companiesroche replac result ofthe strong cash genera ing dual reporting system adopted tion core businesses concluding around new alliances actual adjusted figures financial restructuringthe groups primarily area ofbiotechnology single set offigures con financial condition considerably also secured access promis solidated financial statements please improvednet liquidity increased ing thirdparty innovations turn details billion swiss francsand equity ratio including minority inter purchase ofdisetronic first time annual report ests improved end proposed acquisition ofigen provides details ofthe end mark two important steps compensation paid board roche diagnostics innovation strategy directors member ofthe following completion ofthe sale disetronic worlds second executive committeein additionwe vitamins fine chemicals divi biggest maker ofinsulin pumps created new function ofinde sion late septemberroche roche strengthened position pendent lead directorwhose main completely focused expanding pioneering leader diabetes man tasks lead board periodic core pharmaceuticals diagnostics agementthe acquisition ofigen reviews ofthe chairman ceos businesses helping shape expect complete mid performance chair board healthcare market ofthe future february secures roches member requests ifthe chair man unable result extraordinary eventsthis represents convinced steering right course additional important step thecontinuing evolution ofcorporate roche leading healthcare company governance roche annual general meeting partnership chugai rightsto key patentsallowing tap shareholders april significantly enhanced roches mar new segments ofthe immuno marked number changes ketpresence growth potential chemistry marketone ofthe divisions themembership boardthree injapanthe worlds secondlargest main growth areasandafter entering longserving members board pharmaceuticals marketwe alliance affymetrix fritz gerberandres fleuenberger pleased progress ofthe first start ofwe plan create henri bmeier stepping productrelated collaboration entirely new market dna chips yearall three made roche chugaito develop mra clinical diagnosticsthis allow significant contributions devel treatment ofrheumatoid arthritis therapiesparticularly cancerto opment success rochethe tailored specifically genetic pro board directors executive quality ofour pharmaceuticals files ofdifferent patient groups committee wish thank sin pipeline improved steadily cerely many years dedi last three yearsat end continuing evolve stand cated distinguished servicethe total new molecular entities ards ofcorporate governance board directors propose werein developmentwe achieved transparency line national theelection bruno gehrig number ofclinical advances phase international regulations best lodewijk jrde vink new mem iiand three important highly practices ofthe worlds top companies bers enhance letter chairmanboards independent andcritical operating divisionsour continued patients would perspectivesubject hiselection profitability gains expanding able achieve excellent results annual general meetingbruno global market leadership oncology gehrig appointed independent invitro diagnostics lead director strong development pipeline left continue systematically implement strategy focus innovation independent com firmly believe longterm business success panyin order achieve long term success benefits patients possible policies practices aim doctorsour employees create value maintaining economic social shareholders environmental sustainability good corporate citizenroche roche even better equipped sus haslong accepted responsibilities tainable organic growththe progress towards environment society made strengthened new sustainability report conviction steering franz bhumer lines commitmentfrom right course roche leading roche sustainability report healthcare company published year annual reporti take opportunity draw particularly proud ofinnova attention impressive range tive products hepatitis c ofactivities initiatives described drug pegasysthe hiv fusion inhi first sustainability reportwe bitorfuzeonthe pioneering cancer firmly believe longterm business medicine avastin amplichip success possible poli cypthe worlds first pharmaco cies practices aim create genomic testwhich helping many value maintaining economic people enjoy significantly better social environmental sustain quality oflife often even ability extend life proud fact innovative products allow many people enjoy significantly better quality life often even prolong life tight focus healthcare would like express sincere andits extensive network ofalliances thanks roche employees roche well positioned meet commitmentprofessional challenges oftomorrows health ism hard workwithout care marketthe achievements ofour skill dedication service letter chairman board directors executive committee forthcoming changes board shipfrom roche evolved traditionalhighly directors proposed appointment diversified company focused independent lead director healthcare groupmr gerbers decision step director marks end strengthen roches corporate ofan era spanning yearsduring governance achieved key milestones significantly increased franz b humer chairman board directors ceo value ofour company current board terms ofandreas board directors oeri walter frey also end fritz gerbers current term annual general meeting board end next annual gentlemen agreed stand general meetingwhich held reelection board april mr gerber decided time ago stand addition supporting reelec electionandres fleuenberger tion ofmr oeri mr freythe board henri bmeier likewise proposes election ofbruno gehrig announced intention step switzerland lodewijk jrde directors timethe vink united states new board wishes thank long board members standing members many years ofdedicated distinguished taking current position serviceduring mr gerbers chairman chairman ofthe board ofdirectors board directors executive committeeboard directors franz b humer january left peter brabeckletmathe henri b meier deanne julius andreas oeri horst teltschik john bell rolf hnggi fritz gerber andres f leuenberger andr hoffmann walter frey name year birth term ends election board directors dr franz b humer e chairman dr andres f leuenberger vicechairman rolf hnggi c vicechairman dr hc fritz gerber honorary chairman prof dr john bell c peter brabeckletmathe walter frey b andr hoffmann c dr deanne julius b dr henri b meier dr andreas oeri b dr horst teltschik secretary board directors dr gottlieb keller finance investment committee b audit corporate governance committee c remuneration committee nonexecutive member e executive member committee chairman january board directors executive committee ofswiss life holdingbruno gehrig mrvilliger joined roche holding gmbhbefore vicechairman ofthe governing andsignificantly strengthened appointed secretary board board ofthe swiss national bank expanded human resources directors compliance joined organisation tenureunder officer january professor ofbusiness eco leadershipinitiatives heads group function corpo nomics university ofst gallen roche connect employee equity plan rate serviceswhich comprises headed swiss institute successfully introducedfrom corporate lawcorporate safety banking financeprofgehrig mr villiger also environment corporate human began career union bank responsible site services basel resourcesgottlieb keller retain switzerland kaiseraugst post secretary boardthe board ofdirectors named andreas lodewijk jrde vink founding markus altwegghead ofthe vitamins greutera lawyerto succeed mr keller member consultant ofblackstone fine chemicals divisionstepped compliance officermr greuter healthcare partnersbefore founding executive committee willhold post continuing bhphe chairman ofglobal sale ofthe division com serve head ofcorporate auditing health care partnersa private equity pletedhe retired end unit ofcredit suisse first boston years rochemr altwegg mrde vink many years ofexpe member ofthe executive com rience pharmaceuticals industry mittee nearly years began career schering time made significant contribu ploughwhere became president tions success ofthe company ofschering international mov one ofthe key people respon ing warnerlambert sible divisionalisation ofthe became president chief previously highly centralised operating operating officerand chair businesseswas charge ofpharma manpresident ceo switzerlandand became head ofvitamins fine chemicalsthe subject election annual board ofdirectors wishes thank general meeting april markus altwegg distinguished bruno gehrig appointed inde service outstanding loyalty pendent lead director hewillcontinue serve roche member ofthe board ofdirectors ifthe boards proposals adopted offhoffmannla roche ltdbasel chairman ofthe board franz b agroup operating company humer director also serving executive capacity gottlieb akeller appointed head rocheand majority ofseats ofcorporate human resources board held independent member ofthe executive committee directors july mr kellerwho holds doctorate lawjoined roche members executive committee corporate law department daniel villigermember ofthe execu assistant tive committee head ofcorpo chairman ofthe boardin rate servicesstepped became head ofhuman resources executive functions july roche grenzach chairman ofthe inorder pursue personal interests executive board ofroche deutschland board directors executive committeeexecutive committee january richard laube heino von prondzynski william burns franz b humer erich hunziker jonathan kc knowles gottlieb keller name year birth position executive committee dr franz b humer chief executive officer dr erich hunziker chief financial officer controlling william burns pharmaceuticals division heino von prondzynski diagnostics division richard laube roche consumer health prof dr jonathan kc knowles research dr gottlieb keller corporate services secretary executive committee pierre jaccoud statutory auditors roche holding ltd ernst young ltd since principal auditors jrg zrcher since conrad lffel since group auditors pricewaterhousecoopers ag since principal auditor clive aj bellingham since compliance officer dr andreas greuter direct phone number january board directors executive committee group performance group strategy aim leading healthcare company create produce market innova tive solutions high quality unmet medical needs products services help prevent diagnose treat diseases thus enhancing peoples health quality life group performance operating profit ofthe groups togetherroches core pharmaceuticals core businesses exceptional diagnostics businesses posted items rose local currencies salesgrowth local currencies billion swiss francsthe growth swiss franc termssales rate swiss francs rose billion francsboth operating profit margin divisions grew faster respec basis improved furtherrising tive marketspharmaceutical sales results driven mainly divisions upper end ofthe profitabil oncology portfolionotably mabthera ity guidance issued rituxanherceptin xelodaand bythe newly launched hepatitis c drug combined gross cash flow pegasys established products two core businesses strong cellcept neorecormonsales ebitda increasing local roche diagnostics fuelled currencies swiss francs strong performances diabetes billion billion swiss caremolecular diagnostics francsour ebitda margin increased immunochemistry businesses slightly percentage points group performance group strategygroup strategy new paradigm medicine mankind currently cures fraction ofall known diseases still enormous need real advances diagnostics therapeu ticshoweverbudget realities forced governments assess whether equivalentor perhaps betterhealth outcomes attained lower costin factno matter well health systems performpolicymakers payers industrialised coun tries continuously exam ine ways improve efficiency value money healthcare pharmaceuticals diagnostics businesses successful focusing healthcare rightthey also work challenging changing environment together whenever joint approach roche believes healthcare com makes sound medicalhealth eco panies professionals nomic business sense focus developing deploying targeteddifferentiated medical solu diseases increasingly tionswhich many cases reduce defined terms oftheir molecular overall healthcare costs pathologyroches combination core competencies becoming leading researchdriven health importantparticularly care companyroche working rapidly evolving fields like biotechnol ways preserve restore health ogygeneticsgenomics proteomics capabilities diagnostics examplewe know cancer pharmaceuticals enable us innovate single entity broad spec across entire healthcare spectrum trum ofdiseases differ identifying disease susceptibili significantly genetics ties disease screening popula areas ofthe body affect tions risk preventiondiagnosis molecular diagnostic tests identify therapy treatment monitoring differences thus lead way clinically differentiated medicines aim leader every area weserveroche global market recent years roche imple leader diagnostics andas leading mented major strategic initiatives like supplier ofprescription medicines integrated cancer care unit inselected therapeutic areas new roche biomarker program oncologyvirology transplanta leverage discovery synergies tionone ofthe top ten pharmaceuti pharmaceuticals diagnostics cal companies divisions group performance group strategy one ofour objectives create focusing innovation roche aportfolio ofbiomarkers group network force driving enable effective identification ofthe progress towards targeted medicine patients respond best innovationroche pursuing drugs used assess innovation strategy size alone disease progression improve drug countsroches approach safetyifparticipants clinical trials innovation relies stateoftheart chosen basis oftheir pharmaceuticals diagnostics genetic profilethis would help research inhouse global collab reduce attrition rates ofcandidate orative rd network compounds clinical develop mentas pharmaceutical projects could one key element close interplay evaluated early stage roche strategic part nersgenentech californiausa theinterplay diagnostics chugai japanin hold therapeutics promotes majority intereststhese companies targeted use oftodays medicinesit large measure ofoperational also contributes making new drugs independence within clearly defined safer effectivethe us food strategic framework genentech listed drug administration fdafor new york stock exchange examplehas begun approving new chugai tokyo stock exchange drugs labelling includes genetic test informationand scientific commercial col announced plans new guidelines laborations external companies outlining drug companies must universities complement submit information medicines rd capabilitiesthrough alliances affect people differently depending strategic initiativesbiotech genetic makeuproche work become one ofroches main ing closely fda area strengths help ofdiagnostic testsgreat roche divisions major progress made predicting research programmes based thus minimisingside effectsand groundbreaking discoveries ice dosing become far accurate lands decode geneticsour alliance nowtodayfor examplean decode already resulted average ofthe patients receiv identification ofa number ofgenes ing medication derives immediate contribute common diseasesin sustained alleviation ofdisease examplegenetic risk factors symptomsquite apart prob heart attack osteoporosis lem ofdrugrelated adverse events discoveredin additionscientists new technologies genechip decodes pharmacogenomics enable us understand effect clinical trials subsidiary encode gene mutations may developed gene expression assays bodys response medicines predict responsiveness common treatments asthma hyperten sion high degree ofaccuracy group performance group strategyall ofthese projects common goalto enable roche continue anticipating trendswe ahead industry trendsfor examplewhen webecame pioneering investor biotechnology stake genentechwhen acquired pcr andonce againwhen expanded investment japanese health care market two years agowe confident current portfolio ofresearch projects alliances lead new breakthrough products services create value help ing provide solutions unmet medical needswe intend remain true slogan innovate healthcare group performance group strategy edouard nonhodgkins lymphoma nhl one common cancers lymphatic system today thanks mabtherarituxan retired chemist able tend showcase garden mabtherarituxan combination chemotherapy first therapeutic advance years improve survival patients aggressive form nhlpharmaceuticals division brief change change local millions chf currencies chf sales sales roche worldwide prescription group nonprescription medicines otc ebitda operating profit research development employees exceptional items pharmaceuticals successful year pharmaceuticals division sales growing ahead world market even faster rise operating profit thanks strong performance divisions oncology portfolio especially mabtherarituxan roche extended numberone position important therapeutic areawe expect novel products like avastin help us achieve even stronger leadership oncology future new hepatitis c treatment pegasys surpassed expectations first full year market terms sales market penetrationanother milestone launch novel hivaids drug fuzeon nearly licensing agreements new technologies products concluded complement strong internal research organisation pharmaceuticals outstanding year ebitda totalled million swiss francs pharmaceuticals divisionwe turned ofsalescompared pre impressive performance sales vious year cancer transplantation anemia prescription medicines prescription drug sales divisional sales medicines growing strongly pegasys excluding otc totalled million copegus surpassing expectations swiss francs increase local currencies launch fuzeon major markets swiss francsoperating profit exceptional items reached mil william burns head pharmaceuticals division lion swiss francsand operating profit marginat also yearebitda increased million swiss francsor ofsales divisions oncology portfolio continued major contributor meeting commitment growth growthwith sales rising pharmaceuticals division deliv million swiss francsled top ered good performance selling productmabtherarituxan meeting commitment achieve launch ofpegasys copegus strong growth product sales new combination regimen profit hepatitis cmet early successsur passing expectations regarding sales sales increased local curren market penetrationfuzeonour cies swiss francs novel hivaids therapyhas million swiss francseven without launched markets worldwide newly integrated chugaisales grew cellcept neorecormon posted faster global marketnew accelerated growthwith products established roche products accounted experiencing doubledigit gains halfofsales growthoperating respective indicationssales profit exceptional items rose rocephin remained stable due even faster salesadvancing early start ofthe flu season local currencies swiss united statessales ofour flu drug francs million swiss francs tamiflu increased sharplyin line despite substantially higher expendi expectations roaccutaneaccutane tures new drug launches experienced sales erosion due many highly promising projects generic competition development pipelinethe pharmaceu ticals division posted another signifi oncology portfolio mabtherarituxan herceptin xeloda bondronat kytril furtulon cant increase profitabilityrecording neupogen neorecormon roferona operating profit margin neutrogin picibanil exceptional itemscompared growth rates based local currencies pharmaceuticalsabovemarket growth regions pharmaceuticals sales millions chf roches prescription medicines posted abovemarket sales growth key regionsthanks strong sales genentech rochesales north america increased signifi cantly outpacing marketin europe prescription drug sales accelerated doubledigit rangethanks pri marily good sales ofpegasysneo recormon oncology franchise strong sales increase recorded relatively sluggish japanese mar ket ascribed mainly con solidation ofchugai since october aboveaverage underlying organic growthas result ofits alliance chugairoche ranks fifth worlds secondlargest pharma ceuticals marketin latin america roche numbertwo phar maceutical companysales returned tomidsingle digit growth still declining marketin rapidly developing markets eastern europe china roche growing quickly strongly positioned indus ofallthey provide patients physi try leader cians new better therapeutic options pharma strategy leadership key therapeutic areas innovation management leveraging focusing growth roche rd productivity improving rd focus key areas ofhigh unmet med productivity one ofthe greatest ical need core skills challenges currently facing pharma competencies make difference ceutical industrydespite huge ad include oncologyvirology vances science technologyrd transplantation medicine anemia productivity seems stalled one ofour major goals leader andthe number ofapprovals new every area serve medicines falling roche believes future ofthe roches innovation strategy built pharmaceutical industry lies innova network links strong tionnovel drugs proven medical house capabilities ofgenen benefits likely tech chugai independently approved regulators reimbursed operating associated companies healthcare payers important broad array oflicensing alliance pharmaceuticals gross sales ie sales deducting cash discounts roche worldwide prescription group japan others latin america sales region europe north america roche worldwide prescription group central nervous system infectious diseases metabolic disorders cardiovascular diseases dermatology inflammatory diseasesbone diseases transplantation virology sales therapeutic area others oncology anemia partners around worldinnovation roche strengthened posi management essential tion worlds numberone oncol building current strong pharma ogy companywith billion ceutical pipeline swiss francs sales growth rate local currenciesour cancer ability structure agreements medicines remain largest tailored interests needs fastest growing product portfolio parties whether single currently account ofour pre producta technology entire scription drug saleswith three portfolio resulted roughly new major oncology productsmabthera pharmaceutical alliances mak rituxanherceptin xelodaa ing us leader areain strong pipeline includes avastin broadened ten ofour ongoing alliances tarcevaplus alliances develop enhance value parties number ofadditional drug candidates included memory ipsen making important contribu alliancesour virology agreements tion improving survival quality withmedivirtrimeris stressgen oflife cancer patients number oftechnology research licences mabtherarituxan worlds first therapeutic monoclonal antibody therapeutic areas nonhodgkins lymphoma nhlone oncology cancer second ofthe common cancers ofthe common cause ofdeath many indus lymphatic systemnhl affects approx trialised countrieseach yearmore imately million people worldwide million new cases ofcancer claims estimated lives diagnosed worldwideand yearmabtherarituxan used million cancer deathsin recent years inboth indolent aggressive major advances forms ofnhl achieved sales drug treatment ofcancerand promis billion swiss francs ing new approaches develop indications contributed double mentthe global market cancer digitgrowth ofin september medicines forecast reach nearly mabtherarituxan approved billion swiss francs japan treatment ofaggressive billion swiss francs nhland national institute pharmaceuticalsa year becoming worlds topranked womens doubles player corina toface deadly new opponent learned rare form ofleukemia forced toput career hold afterjust months chemotherapy however hercancer remission enabling enter us open played benefit cancer research every ace corina served roche donated dollars friends cancer research washington dc clinical excellence nice herceptin monoclonal antibody united kingdom issued positive rec used targeted treatment ommendation indication breast cancerthe common cancer clinical studies shown thatirre among women worldwidethe spective ofagepatients aggressive medicine tailored specific nhl treated mabtherarituxan patient subgroup herpositive combination standard chemo tumoursa genetically differentiated therapy improved chance aggressive tumour type accounts survival three yearstrial data approximately ofall breast announced december showed cancersherceptin sales rose mabtherarituxan combination million swiss francsmaking chemotherapy also represents solid gains major marketsthe major clinical breakthrough increasingly widespread use ofher firstline treatment ofindolent lym tests major growth driverfol phomathese data expected lowing evidence combined use result expanded indication ofherceptin taxol herposi potentially doubling number tive metastatic breast cancer patients ofpatients indolent nhl prolongs lifea recent study simi could benefit treatment larly shown combination mabtherarituxana regulatory filing herceptin taxotere significantly combination submitted improves patient survival compared eu authorities january taxotere alonebased two trials halted much ear positive resultsroche filed mar lier planned interim analysis keting application combination revealed primary efficacy end ofherceptin taxotere euro points already reached pean unionwe expect approval pharmaceuticals major product approvals launches product generic name indication country bondronat ibandronate prevention skeletal events patients breast cancer bone metastases eu bonvivaboniva ibandronate treatment prevention postmenopausal osteoporosis usa switzerland fuzeon enfuvirtide treatment hiv eu usa switzerland invirase fortovase ritonavir saquinavir ritonavir ritonavirboosted regimen hivaids usa mabtherarituxan rituximab aggressive nonhodgkins lymphoma japan neorecormon epoetin beta every two weeks renal anemia eu pegasys peginterferon alfaa hepatitis c japan raptiva efalizumab psoriasis usa renagel sevelamer hcl hyperphosphatemia japan valcyte valganciclovir prevention cytomegalovirus infection solid organ transplantation eu prevention cytomegalovirus infection kidney heart kidneypancreas transplantation usa xeloda capecitabine breast cancer japan xenical orlistat pediatric exclusivity usa xolair omalizumab asthma usa includes supplemental indications updated end january genentech chugai ongoing clinical develop theresults ofa largeongoing trial ment programme herceptin xeloda monotherapy adjuvant aimed also establishing drug treatment ofpatients colorectal combination hormonal treatment cancer expected adjuvant setting bondronat currently indicated xeloda sales continued strong management ofhypercalcemia upward trendgrowing abnormally elevated levels ofcalcium united states sales ofthe product blood cancer patientsover advanced tumouracti patients worldwide vated oral chemotherapeutic agent treated product datesales used treat breast colorectal totalled million swiss francs cancerscolorectal cancer third october bondronat gained eu common cancer men approval prevention ofskeletal womenin xeloda approved events pathological fractures bone treatment ofbreast cancer complications requiring radiotherapy japanroche also conducting several surgery patients breast pivotal trials xeloda different cancer bone metastasesthe new combinations treatment ofcolo labelling also reflects ability rectal breast cancer adjuvant bondronat significantly reduce metastatic settingsin addition metastatic bone painroche antici pharmaceuticalsjane totally focused swing shes longer weighed memories terrible moment learned cancer returned even worse spread bones organs diagnostic test established candidate treatment herceptin within weeks starting combination therapy showed significant improvement today active australian feels fit healthy test results normal range pates strong uptake new indi andin third key marketgermany cationwhich substantially increases sales doubled since number ofpatients benefit drug another potential side effect chemotherapy neutropeniaan oncology supportive care roche abnormally low level ofwhite blood also working ways reduce side cells play essential role effects complications ofcancer defending body bacterial therapyour supportive care products infectionsneutroginfor treat help alleviate suffering ofcancer ment ofthis conditionis one oftwo patients significantly improve chugai products among roche quality oflife groups topselling prescription medicines achieved sales kytril potent antiemetic used million swiss francs patients receiving chemother apy radiation therapy anemia anemia occurs undergone surgerythe product number ofred blood cells falls posting steady sales growth andthanks normalthus starving body ofoxy highly competitive profileis genit seen ofpatients recapturing market share fiercely impaired renal function due contested segmentin united states chronic kidney disease products clinic market share ofpatients cancerpotential increased longterm effects ofanemia cardio japan kytril vascular disease renal patients reinforced leadership position reduced survival patients increasing market share cancer even death ifit left pharmaceuticals topselling products roche worldwide prescription group change sales local product generic name indication millions chf currencies mabtherarituxan rituximab nonhodgkins lymphoma neorecormon epogin epoetin beta anemia rocephin ceftriaxone bacterial infections cellcept mycophenolate mofetil transplantation herceptin trastuzumab metastatic breast cancer pegasys copegus peginterferon alfaaribavirin hepatitis c xenical orlistat weight loss weight control roaccutaneaccutane isotretinoin severe acne xeloda capecitabine colorectal breast cancer nutropin protropin somatropin somatrem growth hormone deficiency kytril granisetron nausea vomiting induced chemotherapy radiation therapy following surgery tamiflu oseltamivir treatment prevention influenza b dilatrend carvedilol chronic heart failure hypertension coronary artery disease pulmozyme dornase alfadnase cystic fibrosis neutrogin lenograstim neutropenia associated chemotherapy cymevene valcyte ganciclovir valganciclovir cytomegalovirus infection activase tnkase alteplase tenecteplase myocardial infarction viracept nelfinavir mesylate hiv infection madopar levodopa benserazide parkinsons disease lexotan bromazepam anxiety tension states jointly marketed roche genentech marketed chugai untreatedthe global market anti neorecormon alone achieved sales anemia products currently estimated million swiss francsan increase worth billion swiss francs ofthe use ofthis medicine oncology continues rise sharply roches neorecormon chugais successful product differentiation epogin among leading products improved market penetration con treatment ofrenal anemia tributed impressive rise europe japanrespectivelycom sales segmenta marketing bined sales ofneorecormon application neweasytouse neo epogin showed strong doubledigit recormon formulation onceweekly increase million swiss francs treatment ofanemic patients lym neorecormon achieved significant phoid malignancies recently sub market share gains europewhere mitted eu authorities regulatory authorities approved new regimen april dialysis roches ongoing commitment patients stable hemoglobin levels improving anemia therapy led pharmaceuticalswhen joyce whos teacher diagnosed kidney failure lucky one respect didnt wait long asuitable donor organ akidney sister spared spend additional hours every week dialysis machine prevent body rejecting new kidney joyce takes immunosuppres sant medication therapy lifelong lowtoxicity cellcept amajor advantage development ofcera continuous immunosuppressants minimal erythropoiesis receptor activatoran toxicity like cellcept innovative compound currently tested clinical trialsglobal filings roches immunosuppressive agent ceraincluding submission cellcept topselling branded united statesare planned product united states pre venting organ rejectionwith sales transplantation transplantation totalling million swiss francs alifesaving measure many people accelerated growth rate organ failureworldwidemore cellcept remains one ofour solid organs trans important productsdata pre planted yearand number sented reaffirmed products persons living transplanted safety efficacy showing organ estimated roughly unlike immunosuppres advances transplant surgery santstreatment cellcept paralleled improvements increase risk ofcancer trans immunosuppressive therapy prevent plant patientssales ofzenapaxwhich organ rejectionas resultthe major used combination cellcept ity oforgan recipients die ofother prevent acute kidney transplant causes fully functional trans rejectionshowed slight decrease plants time oftheir death accordinglycliniciansattention combined sales ofvalcyte cyme shifted prevention ofacute rejec vene grew ofits tion avoidance oflongterm toxici potency simple dosing schedule tieswith use ofrelatively toxic valcyte increasingly medicine agents reduced favour choice preventing treating pharmaceuticals cytomegalovirus infections egcmv hiv become worldwide pan retinitisinitially approved use demicat end estimated hivinfected patients coinfected million people living cmvthe product gained important hivaidsincluding million chil approvals last year european dren age ofwhile access union united states use basic medical care remains solid organ transplant patients pressing issue many parts ofthe cmv infection worldthe growing prevalence ofdrug resistant strains ofhiv poses con virology hepatitis c virus hcv stant challenge pharmaceutical cause acute liver inflammation industry develop new therapeutic liver cancer leading reason optionsroche forefront liver transplantationmore efforts combat hiv infection million people around world aids committed dis infected hcvand mil covering developing innovative lion new cases occur year new drugs diagnostic tests aid battle since launch ofpegasys copegus means roche offers new last year fuzeonthe worlds first combination treatment proven fusion inhibitorwas approved efficacy chronic hepatitis csales united states europe march reached million swiss mayrespectivelyfuzeon belongs francsin month ofdecember first new class ofantihiv treat pegasys accounted ments seven years first total us interferon prescriptions drug blocks virus hepatitis c even higher enters host cellsthanks new prescriptions diseasesales novel mechanism ofactionit offers ofthe combination therapy new hope patients devel driven high efficacysimple oped resistance antiretroviral convenient dosing good tolerabil therapiesfuzeon available ity profilepegasys copegus countriesand important available treatment launches expected near hepatitis c countries futuresales totalled million october pegasys monotherapy swiss francsroche partner approved japancompleting reg trimeris actively working accel ulatory approval process major erate uptake offuzeon us markets worldwidelabelling changes marketmajor physician patient approved last summer european education initiatives continue union resulted additional com ensure prescribers petitive advantagesunder new patients informed signifi labelling liver biopsy longer cant clinical benefits fuzeon offers required start oftreatment manufacturing improvements duration dose ofcopegus increased production output ensure therapy based infecting adequate supplies viral genotype fuzeon pharmaceuticalsjames devastated learned hiv positive three years live years ago meantime medical science achieved stunning breakthroughs diagnosis treatment hivaids virus changing develop ing resistance drugs used combat fuzeon first truly innovative new hiv medicine seven years given james art lover lives uk new hope time devote community projects important protease inhibitors another class patents enforce existing patent antihiv medicines pioneered rights hivaids medicines rocheand still mainstay worlds least developed countries ofmany hiv regimensnevertheless subsaharan africamoreoverroche combined sales ofour products supplies protease inhibitors classviraceptinvirase fortovase countries noprofit pricesfurther declined million information topic found swiss francsviracept remains sustainability report pressure competitor products wwwrochecom also affected last year additional price reductions important markets primary care primary care contrastsales ofinvirase segment market products european union rose helped xenicaldilatrend tamifluand approval ofa new regimen mg number ofinnovative medicines invirase mg ritonavir pipeline could significantly growing recognition ofthe drugs effi strengthen position segment cacy safetythe regimen next years also approved united states decembernew dosage strengths xenical remained leading viracept invirase help reduce weight management medicine number oftablets patients sales declined million take daily make products swiss francs line market trends competitive overweight obesity reached epidemic proportions united support global fight statesincreasinglyyoung people aidsroche decided file also affectedcurrentlyabout pharmaceuticals margaret contracted hepa titis c blood transfu sion disease went unnoticed years liver trans plant seemed unavoidable specialist recommend ed take part clinical trial pegasys today isnt trace virus left blood thanks pegasys im healthy says active floridian thats good news grand children adolescents us obeseand sales growing million overweightadolescents swiss francswell established hyper obese greater risk ofbeing tension coronary heart disease obese adults ofdeveloping seri dilatrend benefited late ous health problemsincluding type new positive clinical data diabetes heart diseasethey also comet study confirming increased risk ofmortalityin drug confers significant survival december fda approved benefit patients chronic heart labelling use ofxenical manage failureroche expects sales decline ment ofobesity patients aged dilatrend going yearsthe reimbursement landscape offpatent several major european weight loss drugs continues markets beginning ofapril challengehoweverpositive reimburse ment decisions xenical sweden sales oftamiflu rose remarkable switzerland encouraged us million swiss continue efforts areadata francsdue severe influenza published december land break season mark xendos show xenical japanwhere surveillance reports indi prevent onset oftype diabetes cate million people provide additional evidence infectedand early start favour ofreimbursement flu season united stateswith least million cases dilatrenda leading beta blocking reported farexperts expecting agent hypertensionchronic heart equally severe outbreak japan failure coronary artery disease improved performance considerably pharmaceuticalsroches new bisphosphonatebonviva significantly enhance pharmaceuti boniva ibandronatewas approved cal development pipeline terms bythe us food drug administra ofquantityqualityand balance tion fda may treat ment prevention ofosteoporosis rd pipeline currently postmenopausal women received strongwith new molecular entities apositive opinion use nmesincluding optin oppor indication european unions tunitiesthe quality ofthe portfolio committee proprietary medicinal steadily improved past products cpmp octoberthe three yearsand attrition rate product jointly developed latestage products fallen rela glaxosmithklinethe aim make tively low levels period longterm treatment adherence easier terminated projects patients postmenopausal phase phase ia total osteoporosis thus offer practical projects terminated phase ii effective therapy condition including levovirin fusion based encouraging phase iii inhibitor tour projects trial dataa supplemental filing balanced across different stages simplermore convenient dosage regi developmentwith projects phase men submitted projects phase projects inphase iiand projects phase iii major products rocephin sales portfolio extends across multiple remained stable early respiratory therapeutic areaseach ofwhich season united states compen targeted group major sated continued generic erosion europeespecially france ger continuing drive create clinically manyfollowing expiry ofthe italian patent end ofdecember differentiated medicines expect european sales ofrocephin decline however seamless rd process industry demand expected remain strong leadership building productive united stateswhere product continue protected patent strategic alliances bearing fruit substantial portfolio new sales ofroaccutaneaccutaneroches innovative medicines today one medicine severe acnefell million swiss francs best industry decline largely due market jonathan kc knowles head global research entry ofcompeting generics united states europe research development creative internal research devel opment alliances external innovators enabled roche pharmaceuticals growth areaand also balanced designated priority review terms oflevels ofdevelopment riskwe fdaan eu filing submitted currently research projects december spanning seven therapeutic areas development projects ten thera tarceva cancer medicine designed peutic areas interfere molecular signal stimulates tumour cell growth key development projects many solid tumourstwo phase iii moving ahead plannedwe achieved studies patients nonsmall cell important clinical advances phase ii lung cancer meet primary three highly promising projects endpointa monotherapy trial cera anemia mabthera tarceva pretreated lung cancer rituxan mra rheumatoid patients proceeding plannedwith arthritis already eligible enter results expected first quarter phase iiiwe expect report five roche continuing clinical phase ii products development oftarcevaas drug may useful treating variety oncology results phase iii cancers trial latestage cancer drug avastin showed increase sur joint programmes develop new vival duration patients received oncology products kosanipsen avastin plus chemotherapy firstline antisoma progressing track treatment metastatic colorectal canceravastin monoclonal anti anemia development ofour inno body designed block vascular vative anemia treatment cera growth factor critical worldwide use anemic patients development ofnew blood vesselsa cancer renal disease moving ahead process known angiogenesisangio plannedresults phase ii genesis essential growth clinical study shown cera solid tumours metastatic highly effective dialysis patients spreadinterrupting process chronic renal anaemiafurthermore potentially stop slow tumour results phase iii study showed growth even starve existing tumour cera effective treating anemia tissue make shrinkavastin rep multiple myeloma cancer patients resents promising new approach phase iii studies renal patients treatment ofcancerwith broad scheduled start early potential use number ofsolid phase iii trials cancer patients tumoursand could useful com due start end ofthe year plement conventional chemother apyroche genentech jointly transplantation profiling ofthe novel develop product commer immunosuppressant isa post cialise genentech united transplant patients continued stateschugai japan roche additionroche inlicensed drug countriesan application candidate potential uses trans approval ofavastin filed plantation rheumatoid arthritis united states september cardioncurrently preclinical pharmaceuticalsdelif ecnalab dna ytilauq ytitnauq fo smret ni enilepip decnahne noitacidni iii esahp ii esahp esahp esahp noisnetxe enil rojam eman cireneg epyt tcudorptcejorp aera cituepareht aimena detaler recnac dna aimena laner tnemtaert aimena noitareneg txen r aimena aimena tnemtaert aimena r sesaesid yrotammalfni ydobitna lanolconom r enobnoitammalfni esaesid lewob yrotammalfni tsinogatna nirgetni r sitirhtra diotamuehr rotibihni esanik r sitirhtra diotamuehr rotibihni esanik r sitirhtra diotamuehr tsinogatna nirgetni r siroropoetso fo noitneverp dna tnemtaert tanordnabi etanohpsohpsib avinobavivnobr yliad gm sisoropoetso fo noitneverp dna tnemtaert vi nettimretni dna laro ylhtnom sitirhtra diotamuehr bamixutir ydobitna lanolconom naxutirarehtbam sitirhtra diotamuehr ydobitna lanolconom armr setebaid ii epyt rotaludom rotpecer raelcun r msilobatem ytisebo rotaludom rcpg r setebaid ii epyt rotibihni emyzne r setebaid ii epyt rotaludom emyzne r setebaid ii epyt rotibihni emyzne r setebaid ii epyt rotaludom rotpecer raelcun r setebaid ii epyt rezitisnes nilusni r bnapaj ni tnempoleved tatsilro rotibihni esapil lacinex stnemdnema lebal esaesid sremiehzla rotaludom rcpg r metsys suovren noisserped rotaludom rcpg r esaesid sremiehzla rotibihni emyzne r esaesid sremiehzla rotibihni emyzne r esaesid sremiehzla rotibihni emyzne r yteixna dna noisserped rotaludom rcpg r yteixna dna noisserped rotaludom rcpg r sromut dilos rotibihni emyzne r ygolocno sromut lacigolotameh ygolocno ydobitna lanolconom r recnac nairavo bamomutmep ydobitna lanolconom r recnac tsaerb ydobitna lanolconom r sruomut dilos enolihtope rotibihni emyzne r sruomut dilos rotibihni emyzne r sruomut dilos rotibihni emyzne r sruomut dilos bamuzutrep ydobitna lanolconom gratinmor sruomut dilos nacetomolfid rotibihni emyzne r sruomut dilos rotibihni emyzne nbr sruomut dilos binitolre rotibihni esanik avecratr seitivitca tnempoleved tnioj bamuzutsart ydobitna lanolconom nitpecreh recnac tsaerb fo tnemtaert tnavujda aimekuel citycohpmyl cinorhc bamixutir ydobitna lanolconom naxutirarehtbam enil tslhn tnelodni noitanibmoc citatsatem dna tnavujda enibaticepac adolex recnac noloc fo tnemtaert recnac tsaerb tnavujda recnac latceroloc citatsatem enil ts bamuzicaveb ydobitna fgevitna rnitsava noitanibmoc ni sromut dilos rehto dna yparehtomehc htiw esaesid yranomlup evitcurtsbo cinorhc rotibihni emyzne r yrotaripser amhtsa tsinogatna nirgetni rg g amesyhpme tsinoga rotpecer raelcun r noitcejer tnalpsnart laner etuca rotibihni nirueniclac r tnalpsnart ecnenitnocni yraniru sserts rotaludom rcpg r ygoloru noitcnufsyd elitcere elam tsinoga rcpg r ecnenitnocni yraniru dexim dna sserts rotaludom rcpg r c sititapeh rotibihni esaremylop r ygoloriv telbat gm wen rivaniuqas rotibihni esaetorp esarivni b sititapeh cinorhc aafla norefretnigep norefretni detalygep sysagep noitalumrof wen esaesid vih etalysem rivaniflen rotibihni esaetorp tpecariv noitcefni lairetcab citoibitna r sesaesid suoitcefni chcetneneg hguorht noitapicitrap sitirhtracitairosp bamuzilafe ydobitna adcitna milenax ylremrof avitpar bafuhr sitnecul noitareneged ralucam detalerega tnemgarf ydobitna lanolconom baf dma ylremrof ciaguhc hguorht noitapicitrap amoleym elpitlum ydobitna lanoloconom mha sisoropoetso enomroh dioryhtarap tnanibmocer shc recnac tsaerb lxtetamatulgylop chc sesatsatem enob ydobitna lanoloconom lac sisoropoetso evitavired nimativ de esaesid traeh yranoroc tnadixoitna ob siseraportsag tsinoga nilitom mg ymotcetapeh tsop rotareger revil lav egahrromeah dionhcarabus savetna nemow lasuaponemtsop ni recnac tsaerb elozortel aramef nemow lasuaponemtsop ni sisoropoetso lch enefixolar atsive dseitinutroppo nitpo emordnys yranoroc etuca stnemgarf ydobitna lanolconom bafft hcetneneg ydobitna nlm esaesid lewob yrotammalfni ydobitna lanolconom pdl yllamrof gnilaeh dnuow rotcaf htworg lailehtodne ralucsav fgev noitcefni lagnuf lagnufitna lab lagnufitna aelisab noitcefni lairetcab citoibitna lab citoibitna esrever edisoelcunnon r rividem esaesidvih rotibihni esatpircsnart setebaid ii epyt mib r nespi sruomut dilos tnega gnittegrat ralucsav aaxmd amositna era eseht fo enilepip tnempoleved snoisivid slacituecamrahp eht ni semn yltnerruc era ereht sesaesid yrotammalfni rednu detsil si ra srentrap lanretxe ii esahp ni era gnitset lacinilc esahp deretne evah esahp tnempoleved egatsylraeni ygolocno rednu dna sesaesid enob nespi secneics nohpyrg iii esahp ni dna ton yam stcejorp emos snosaer evititepmoc rofb isohcetneneg hcetneneg deifitnedi neeb evah akinhcetosi enilkhtimsoxalg tnempoleved lacinilc ot lacinilcerp morf noitisnart esahp noitadilosnoc llufc rezifpnorugua cedihcetneneg stneitap ni ylbissop dna sreetnulov yhtlaeh ni seiduts laitini esahp tcudorp eht esnecil ot thgir eht sniater ehcord oyknas iaguhc stneitap ni seiduts gnidnifesod dna ytilibarelot ycaciffe ii esahp sitravon slacituecamrahp yromem ycaciffe dna ytefas fo noitamrifnoc lacitsitats rof stneitap ni seiduts elacsegral iii esahp seititne ralucelom wen stneserper epyteulb yllil ile amositna semn secneicsoib nasok rebmeced fo sa tnerructestingthe compound expected research projects help roche consolidate position major therapeutic areas december two key medical areas virology pegasys fulfilling pro metabolic disorders virology mise potent antiviral therapy oncology vascular diseases inhcv patients normal alt whoare often considered mild urogenital diseases hepatitis routinely con inflammatory diseases sidered treatmentpegasys demon central nervous system strates excellent results reducing viral loadoffering potentially curative treatmentresults first autoimmune diseases autoimmune largescale global trial ofhepatitis c diseases occur immune sys patients coinfected hiv tem attacks bodys cells rather become available foreign microorganismsmore clinically distinct autoimmune two trials phase ii iii diseases identifiedeach pegasys hepatitis b confirmed affecting body different way superior standard rheumatoid arthritis rafor exam medicines currently prescribed pleis characterised joint inflam diseasethese findingsalong data mation whichdespite treatmentcan hepatitis b trialswill form result progressive joint destruction basis filing pegasys treat ultimately lead loss offunction ment hepatitis b ofthe affected jointsthe cause billion people worldwide thisautoimmune disorder unknown infected hepatitis b virus hbv nearly million people suffer approximately million people raworldwide chronic hbv infectionsan esti mated million people die year rochegenentech idec devel hepatitis b complications oping mabtherarituxan treat ment ofrathe efficacy safety roche trimeris decided data first proofofconcept proceed clinical development trial drug ra good ofthe potential antihiv medicine given alone combination ofdifficulties achiev drugsmabtherarituxan ing technical profile required promises substantial sustained current formulationin january improvements treatment outcomes two companies underscored could represent entirely new ongoing commitment improving approach treatment ofra hiv care signing research agree another roche biopharmaceutical ment develop new generation developed ra mrathis fusion inhibitorsthe new agreement roches first codevelopment project focuses investigation ofimproved chugaivery positive data formulation delivery technologies european phase ii study pre peptide fusion inhibitors sented last year major international pharmaceuticals roche consumer health knows congresses united states europephase iii testing ofmra build strong brands years way japan since first brands helping create value halfof slated start year united states euro roche group business pean union competitively advantaged growing roche aspreva pharmaceuticals faster marketwe intend formed unique alliance develop cellcept use several continue developing brands autoimmune diseasesin additionthe commercial alliance roche position strength protein design labs pdl richard laube head roche consumer health restructured allow pdl develop zenapax indications transplantation primary care current phase ii pipeline includes potential medicines stress urinary incontinencedepres sion prophylaxis chronic treatment ofasthma leading otc brands change type diabetes disease recog sales local product uses millions chf currencies nised global pandemic ofenor aleve naproxen analgesic mous magnitude created supradyn multivitamin comprehensive portfolioincluding bepanthen skin care insulin sensitiser rcurrently rennie antacid phase ii development redoxon vitamin c nonprescription medicines otc sales ofnonprescription roche consumer health products medicinesincluding sales chugai japangrew local currencies swiss francs million swiss francs skin hair care analgesics others roche consumer health rch gastrointestinal products achieved strong organic growth sales therapeutic area excluding chugaisales increased local currencies million vitamins swiss francssubstantial sales growth reported almost marketsbut especially asiapacific region eastern europethe ten topsell ing brands posted robust growth pharmaceuticalsdemonstrating rchs excellent pharmaceuticals division remains brandbuilding capabilitiesbepan committed achieving operating thenredoxon aleve profit margin approaching main growth driverschugais otc beforeexceptional items end sales line expectations ofthis equivalent previ ously announced goal ofan adjusted operating profit otc busi margin approaching ness totalled million swiss francs exceptional itemsa gain local currencies swiss francs previous yearthe operating profit margin decreased slightly due lower profitability chugais otc business invest ments develop xenical orlistat otc product outlook based achievements pharmaceuticals division solid mediumterm perspectivewith sales expected grow faster world market anticipate continued strong growthfor cancer productsthe addition ofavastin oncology portfolio major milestone set stage continu ing leadership oncology sector anticipate increase sales pegasys andfuzeon expect neo recormonepogin cellcept remain major sales driversrocephin roaccutaneaccutane expected play less important role overall portfolio thanks current future productswe ideally positioned sustained growth core areas competencyoncologyvirology anemiawe expect maintain current strength specialty care sector pharmaceuticals thanks treatment pegasys margaret lives miami completely cleared hepatitis c infec tion viral load monitoring reliable highly sensitive molecular diagnostic tests show blood virus free many patients viral diseases roches efforts align diagnosis treatment response monitoring vitally important pcrbased blood tests enable doctors determine stage patients disease thus help guide decisions dose duration therapydiagnostics division brief change change local millions chf currencies chf sales sales diabetes care near patient testing centralized diagnostics molecular diagnostics applied science ebitda operating profit research development employees exceptional items diagnostics two major acquisitions disetronic insulin pumps igen immuno chemistry strategic alliance affymetrix dna chips continued aboveaverage sales gains combined make successful year roche diagnostics despite limited global market growth division maintained global leadership fact increased preeminence competition growing market share posting substantial doubledigit increase profitability diagnostics provision information generated large number attractive new productswith clinical decisions based play new product launches roche ever increasing role healthcare diagnostics demonstrated capacity innovation market future global aboveaverage growth worldwide market leader aim successful division recorded significant sales area assays gains regionsdespite weak negative growth worlds major systems diagnostics markets heino von prondzynski head diagnostics division sales north america double market averagein europe market characterised healthcare budget restrictionssales growth sales japan rose compared despite decline market asa wholein asiapacific iberialatin america roche diagnos global market lead extended tics expanded market share sales diagnostics division doubledigit sales growth totalled million swiss francsa yearonyear increase diagnostics strategy local currencies swiss helping shape diagnostics francsroche diagnostics thus grew market future roche twice fast global invitro theonly diagnostics company diagnostics market supplies market segmentsfrom research scientists right profitability measures also continued consumersto maintain fasterthan improveoperating profit average growthwe pioneering exceptional items local developments new areas currencies million swiss promise significant medical benefit francswith ebitda rising local currencies million swiss aim consolidate leadership francsthe operating profit margin inthe invitro diagnostics market percentage points focusing highvalue growth areas ebitda margin advanced diabetesmolecular diagnostics percentage points immunochemistry expand ing health information market divisions profitable fastestgrowing business areas dia innovation management building betes care molecular diagnostics strengths developing new markets immunochemistry products promote development ofnew main contributors markets maintain technology strong performancefurther growth lead futurewe pursuing diagnosticsthreepronged strategystrengthen diagnostics sales millions chf inhouse research development pursue acquisitions alliances leading technology companiesand promote internal ventures accordinglywe invest financial human resources research development competitors resulting innovative power demonstrated fact gen erate ofsales products launched last three yearsin alonethe diagnostics division filed patent applications immunochemistry product line annually growth area ofmolecular diag nostics building existing signing licensing agreement portfolio expanding oncology affymetrixwe took challenge pharmacogenomicsfocusing ofbuilding market dna chips diagnostic products support early clinical diagnostics scratch diagnosisdisease prevention tar amplichip cypa test pro geted treatment vides information individual metabolic variations affect action acquisitions alliances complement ofcertain widely used drugs differ strengths give us access ent patientsis first product additional innovative technologies result alliancethe test helps acquisition ofdisetronic avoid adverse drug effects caused strengthened lead incorrect dosage thus represents diabetes segmentby combining pioneering achievement road blood glucose measurement individualised therapeuticswhich insulin pump technologyroche set replace present one drug fits able offer integrated diabetes allapproachanother key alliance management solutionsthe acquisi formedwith epigenomicsaims tion ofigenwhich expect identify new cancer markers complete mid february gives roche unrestricted access divisions internal venture process immunochemistry sectorvalued entering third yearthis billion swiss francsimmuno initiative gives employees oppor chemistry biggest segment tunity implement new business theinvitro diagnostics marketthis ideas incompany startups strategic acquisition place usin currentlyten ventures operating anideal position become market japannorth america europe leader segment medium two ventures strategically long termin last three years important health information sector wehave increased sales ofour elecsys already solid market presence diagnostics gross sales ie sales deducting cash discountsbusiness areas improvement diabetes man diabetes care diabetes care grew agement rely integration local currenciesoutpacing separate market substantial margin technologies blood glucose meas consolidated leading posi urement insulin delivery tion blood glucose monitoring aim ofcreating artificial pancreas asiapacific japan others near patient testing applied science molecular diagnostics europe sales region sales business area north america diabetes care centralized diagnostics iberialatin america million people suffer acquisition ofdisetronicthe diabetesand world health worlds secondlargest supplier organization estimates insulin pumpsis thus important figure rise million strategic moveas result ofthis regularaccurate blood glucose transactionwhich finalised monitoring helps prevent compli may roche offers compre cations cardiovascular disease hensive range ofproducts people thus reducing followon costsroche diabetesfrom glucose monitor diagnostics played major role ing anddata management insulin inshaping trend glucose self delivery monitoring portable glucose meters accurate clinical integration ofdisetronics inter laboratory national sites proceeding according plan already com roche diabetes care expanded pleted countriesroche optimised portfolio ofblood working closely fda glucose monitoring systemsnew ver address agencys concerns sions oftheproven accuchek advan disetronics production processes tage accuchek active glucose documentationwe intend resume meters posted good sales right pump sales us second startas new test strip halfofreinspection fda accuchek compactthe new strip expected take place around gives faster results less blood middle ofthe yearthe burgdorfsite successfully passed european tv additionthe rollout ofaccuchek technischer berwachungsverein goa novelparticularly userfriendly audit end glucose meterstarted end diagnosticsyi sheng already retired diagnosed diabetes today passion ate amateur painter shanghai knows people diabetes lead per fectly normal lives sim ply learn get disease control thanks builtin con venience accucheck advantage monitoring blood glucose levels comes nat urally yi sheng whos simplest brushstroke near patient testing near patient clear market leaderwith market testing leading supplier ofprod share ucts services rapid pointof care diagnosis patientshomes hospital point ofcare segment doctorsofficesambulances inten rapid diagnostic products use sive care unitstotal sales decreased accident scenes intensive care local currencies due units roche steadily improving streamlining ofthe product range market sharekey factors behind early year divestment ofthe high growth segment opti systems drugsofabuse test decision refocus activities ing businesseson comparable basis core business strong sales sales near patient testing rose ofcardiac assays omni blood gas local currencies analysersas result ofthe outbreak ofsevere acute respiratory syndrome worldwide sales ofcoagulation moni sars beginning toring products grew orders blood gas analysers china demand fuelled mainly alone three times planned continuing trend patient selfmoni production output markets toringthe medical economic worldwide yearwe advantages ofselfmonitoring proved ability meet increased documented international demand crisis also made real clinical trialsresulting decisions contribution saving lives increasing number ofeuropean health insurers reimburse costs new multifunctional omni coagulation monitoring another blood gas analyserlaunched segment roche diagnostics mayis already well way diagnostics topselling product lines change sales local product line market segment business area millions chf currencies accuchek glucotrend diabetes management diabetes care cobas integra roche hitachi clinical chemistry centralized diagnostics elecsys immunochemistry centralized diagnostics amplicor tests cobas amplicor molecular clinical diagnostics molecular diagnostics cobas ampliscreen molecular blood screening molecular diagnostics coaguchek coagulation monitoring near patient testing excluding hia homogeneous immunoassays toduplicating strong sales per modular analytics swa formance ofomni c ishighthis trend also reflected growth ofcentralized diagnostics information management steadily significantly outperformed gaining importancein futurecom themarket sales local puterbased systems significantly currencies accelerate enhance medical diag nosticsthis demonstrated againthe elecsys immunochem astudy ofdatacare poc conducted istry product line posted doubledigit inthe netherlands gainswe constantly expanding showed software helps hospi systems test menu added tals achieve substantial time cost new hormone marker assay new savings therapeutic drug monitoring drug concentration tests primary care segment compact systems doctorsoffices multi market response elecsys parameter systems ofthe reflotron probnpa highly innovativefully product line accutrend cholesterol automated test diagnosing chronic testing products posted aboveaverage heart failure monitoring patients growththe rollout ofa new genera response treatmentcontinued tion ofinstruments offering standard bevery positiveit already available ised urinalysis met good market europe united statesand response application marketing approval filed japanin novem centralized diagnostics workflow ber fda additionally cleared elec efficiency crucial laboratory diag sys probnp test risk stratifica nosticswhere cost pressure major tion chronic heart failure acute factorlarge laboratories hospitals coronary syndromemaking first need powerfulintegratedcosteffec assay simultaneously covers tive laboratory systemsaccordingly applicationschronic heart demand modular hightech systems failure common disease western diagnosticscountries high mortality business segmentin rateearly diagnosis deci business area demonstrated capac sive impact progression ity develop innovative invitro diag nostics substantial increase transferred us hema local currency salesas expected tology business back partner sales ofenzymes industrial cus sysmexthis allows companies tomerswhich account relatively focus core competencies small percentage ofrevenuesdeclined increase profitabilityall agreements sysmex outside us unaf sales growth ofblood screening tests fected move tests sexually transmitted dis eases high doubledigit expect complete acquisition rangealong tests hivaids ofusbased igenannounced july hepatitisthese products contin mid february ued key sales drivers strategic move secures rights use ofelectrochemiluminescence molecular diagnosticssuccess based ecl technology also allows us polymerase chain reaction pcr totap new markets one technologywhose development thedivisions largest growth areas substantially pioneered roche immunochemistrywhich accounts using pcrsegments ofdna ofthe invitro diagnostics amplified many millions market thus surpasses even dia copiesmaking possible diagnose betes monitoring roche diag diseases rapidly reliably nostics intends systematically expand market share seg roche diagnostics successfully mentthe acquisition ofigen gives met two major challengesfirstin roche new nonexclusive rights eight weeks developed first permit us fully exploit potential pcrbased test detect virus ofecl technology develop causes sarsa previously unknown elecsys product line respiratory diseasedevelopment thetestwhich research use since acquisition announced onlywas part made possible roche centralized diagnostics goodcollaboration received several large ordersincluding thegenome institute ofsingapore one laboratory chain bioscentia research organisationssecond another schottdorfone inrecord time molecular diagnostics europes largest commercial laborato developed first highly automated riesin additionin signed test detecting west nile virus number ofmajor multiyear contracts donated bloodthe testwhich also including one us hospital detects pathogens belonging organisation amerinet japanese encephalitis virus group introduced united states molecular diagnostics mar canada clinical trials mid ket share ofover roche molecu already identified units lar diagnostics unrivalled leader ofcontaminated donor blood diagnostics major approvals product launches business area product diabetes care test strip accuchek compact blood glucose meter accuchek advantagesensor blood glucose meter new version accuchek go blood glucose monitoring system accuchek active blood glucose meter new version near patient testing omni multifunctional blood gas analyser diavant internetbased service urisys urinalysis system datacare poc centralised data instrument management software omnilink blood gas analyser management software centralized diagnostics elecsys shbg hormone assay therapeutic drug monitoring tests amikacin lidocain quinidine elecsys probnp assay heart disease new indications molecular diagnostics amplichip cyp microarray drug metabolism research use cobas taqman realtime pcr analyser amplicor hpv human papilloma virus test reagent lightcycler factor ii factor v tests thrombosis risk assessment clinical use lightcycler sars assay research use taqscreen west nile virus test clinical trials applied science lightcycler dna amplification system magna pure compact nucleic acid purification system lighttyper instrument snp analysis prionics check lia test bse madcow disease june saw us launchfor research cobas taqman launched useofamplichip cypthe worlds united states june received eu first pharmacogenomic microarray marketing approval shortly thereafter infuture new dna chipbased test system puts realtime pcr tech help physicians select appro nology within reach ofsmall priate medication dosageroche mediumsized laboratories first working obtain approval timegiving roche access new cus united states europe clinical tomer segmentsthe improved tech diagnostic version ofthe test nology offers significant advantages including faster resultshigher sensitiv end united states ity wider measurement range roche launched reagent enables moreoverroche protected qualitative testing ofthe clinically realtime pcr technology many relevant subtypes ofhuman patents worldwidethe european papilloma virus hpvthe leading launch ofthe larger cobas taqman cause ofcervical cancerinitiallythe incombination cobas reagent isavailable use certain ampliprep sample preparation instru specialist diagnostic laboratories mentis scheduled second roche plans launch clinical diag quarter expected nostic version early stimulate growth diagnosticsa decision european patent research development adjustable penetration depth office uphold roches years diagnostics division greater user comfort patent taq dna polymerase repeatedly demonstrated inno akeycomponent ofpcr technology vative strength areas diabetes near patient testing emer brought close lengthy dispute care pcrbased diagnostics gency physicians need fast access patentability ofthis enzyme test results information risk europea court action addition longterm develop factors directly actionable health united states concerning patent ment plans new systems tests informationthis requires innovative isstill pending roche diagnostics also able solutions instruments respond quickly emerging medical clearly defined parameter menusour applied science provider needs marketoriented solutions mediumterm goal include reagents hightech systems sci demonstrated important tests single platform entific industrial researchapplied development record time ofnew form ofmodular desktop science came pressure tests sars west nile virus handheld deviceswe also plan due sluggish economic climate strengthen cardiac marker weak biotech marketespecially roche diagnostics invested portfolio heartfailure test united statesconsequently million swiss francs forthecardiac reader system sales declined local currencies research development newdevelopments howeverthanks established rep utation partner life science diabetes care roche diabetes care also scheduled launch research worldwide following focusing development ofan improved test strip clear realignment towards genomics comprehensive solutionssuch inte coaguchek coagulation monitoring proteomics beginning grated spot monitoring systems glu product line ofa new pointof roche applied science well cose meters combine test strips care data management application equipped future automatic checks ofstrip integrity web functionality lancing system also linked several innovative products launched insulin delivery systems sophis centralized diagnostics centralized use genomics deserve ticated information systemsin addi diagnostics focuses complete solu special mentionan updated version tionwe continuing work tions help diagnostic laboratories lightcycler offers greater versatil develop glucose measurement tech increase productivity reduce ity research applicationsmagna niques require blood costsroche also working steadily pure compacta compact benchtop sample toexpand systemstest menus instrument fasteasy nucleic launches ofnew markers treatment acidpurificationthe new lighttyper enhanced version ofour accu monitoring osteoporosis skin snp analysis snpsor single chek pocket compass diabetes man cancer ofa combined hiv antigen nucleotide polymorphismsare small agement softwarewhich antibody assay planned variations indna may asso compatible insulin pumps yet largely unexplored ciated certain diseasesfinally isslated launch addi field ofproteomics conducting prionics check liaa newfully auto tiona new generation ofinsulin research innovative markers mated test enables detection pumps scheduled launch conditions asrheumatoid arthri bseor madcow diseasein slaugh second halfyearother key projects tis colorectal cancer tered cattlereceived marketing planned launches approval europe two new lancing systemsoneconsid molecular diagnostics molecular ered worldwide first hygiene diagnostics systematically expand safetyfrom accuchek softclix ing pcr product portfolioblood product linethe new model screeningnow secondbiggest diagnostics mountain bike doris got life moving right direc tion mother four doris got heart valve operation fine absolutely vital monitor anti coagulant therapy one little drop blood takes coaguchek provide information needs whenever wherever needs selfmonitoring helps peo ple stay independent market pcr applications currently available virologycontinues gain impor research use certain specialist tancecurrent projects area laboratoriesthese include amplichip include fully automated systems cyp hpv reagent screening donor blood products infectious pathogens applied science years inadditionwe developing new business area successfully served markets womens healthmicro needs ofresearch laboratories biologygenomicspharmacogenomics worldwidefollowing expansion oncology areas refocusing genetics pro teomicsapplied science continue pursuing joint projects meet high expectations ofits affymetrixdecode epigenomics customersthe development ofscien develop clinical diagnostic tests tific services key focus based pcr genechip technol coming yearsalong continued ogydiscover gene variants identify development ofthe lightcycler tech new tumour markersrespectivelyfol nology platform expand range lowing amplichip cypwe intend ofapplications increase sample commercialise dna chipbased tests throughputhighthroughputcycler range ofdiseasesespecially realtime pcr analyser scheduled oncologywe expect first ofthese forlaunch one prod microarrays available research uctin additionwe developing use months aninnovative system rapid pro duction ofcustomisable dna chips plan launch clinical lifescience research diagnostic versions ofseveral products diagnosticskey product launches scheduled business area product diabetes care safe tpro plus lancing systems accuchek softclix lancing system accuchek pocket compass diabetes management software minitron insulin pumps new generation near patient testing coaguchek pts test strip coagulation testing datacare web pointofcare data management software centralized diagnostics elecsys pnp bone formation marker treatment monitoring osteoporosis elecsys treatment monitoring skin cancer sta cephascreen coagulation test hiv combi combined hiv antigen antibody assay urisys urinalysis system molecular diagnostics amplichip cyp microarray drug metabolism clinical use lineararray hcv test hepatitis c virus genotyping lineararray hpv test human papilloma virus clinical use integrated cobas ampliprep cobas taqman systems sample preparation dnarna analysis lightcycler l instrument dnarna analysis clinical diagnostic version lightcycler hsv iii test herpes simplex virus clinical use applied science multiple reagents use genomics research lighttyper sw system snp analysis magna pure lc system nucleic acid purification isolation outlook roche diagnosticsrecent strategic moves disetronicigen affymetrix mean position develop new products markets high growth potential help ofdna microarray cuttingedge technologies aim advance paradigm shift individualised healthcare solutions play leading role developing market health information roche diagnostics track achieve objectives ofabovemarket growth fiscal operat ingprofit margin exceptional items ofaround equivalent previously announced goal ofan adjusted marginof diagnostics corporate governance roche group committed stakeholders strives serve diverse interests customers employees shareholders holders roche non voting equity securities balanced fashion commitment reflected operating businessesfocus value creation management culture conforms modern standards corporate governance groups policy communicating transparently organisational structure committees except presidium board directors chaired independent directors roches board ofdirectors organ ised ensure groups bylaws ofthe board ofdirectors businesses conducted responsibly containing details internal focus longterm value structure ofthe boardthe allocation creationthereforesome years ago ofauthority responsibilitiesthe board ofdirectors ofroche holding mandates ofthe board committees ltd delegated certain responsibilities information control several committeesthese commit mechanisms available board tees dealings corporate manage presidium ofthe board mentare published internet directorsnomination committee audit corporate governance articles committee thebylaws ofthe board ofdirectors finance investment committee wwwrochecom company corporate remuneration committee governance boards bylaws ccoorrppoorraattee ggoovveerrnnaanncceeremuneration members executive committee number number fixed salary fixed salary bonus bonus options options chf chf chf chf awarded awarded fb humer altwegg wm burns e hunziker ga keller jkc knowles rt laube h von prondzynski villiger total employee options issued roche pro rata period october december avicechairman ofthe board may remuneration members atthe request ofany memberconvene executive committee board meeting without attend members ofthe executive ance ofthe chairmanin futuresuch committee received salaries meetings convened vice bonuses stock options shown chairman named independent table remuneration ofmembers lead director board ofdirec ofthe executive committeeand torsonce year roche board additionally received bearer meets assess chairmans perfor share mentioned later section mance absencethis meeting chaired future inde pendent lead director option granted entitles holder purchase one roche non remuneration voting equity security genussschein remuneration members price swiss francsunder board directors terms ofthis longstanding option members ofthe board ofdirectors planthe exercise price closing receive annual remuneration price roche nonvoting equity swiss francs serving board securities trading day remuneration paid chairman roche annual media conferencethe ofthe board service options nontradable must capacity deducted agreed exercised later february salarymembers serving board com onethird ofthese options mittees receive additional compensation subject vesting period ofone year swiss francs time onethird vesting period oftwo expensesremuneration compen yearsand onethird vesting period sation paid nonexecutive members ofthree yearsunvested options lapse ofthe board ofdirectors serving without compensation ifa member aforementioned capacities totalled voluntarily leaves companywhile million swiss francs vested options must exercised corporate governance within limited period oftimeifthey december onethird ofthe tradabletheir fair value options awarded holder date ofissue would exercisable exercise value roughly swiss francs per option swiss francs per optionas based blackscholes formula december options deducting aver exercised member ofthe age twoyear vesting period executive committee option granted entitles event attended members holder purchase one roche executive committee nonvoting equity security price key managers throughout swiss francsthe options roche groupeach attendee nontradable must exercised received one roche bearer share later february onethird time market value ofthese options subject vest swiss francs ing period ofone yearonethird vesting period oftwo yearsand one directors members ofthe execu third vesting period ofthree years tive committee receive annual expense unvested options lapse without com allowances swiss pensation ifa member voluntarily francsrespectivelythe chairman leaves companywhile vested board receives annual expense options must exercised within allowance swiss francsin alimited period oftimeifthey members ofthe executive tradabletheir fair value date committee together received expense ofissue would allowances totalling swiss swiss francs per option based francs onthe blackscholes formula average vesting period oftwo years time ofhis retirement markus altwegg awarded special bonus indirect benefits million swiss francs recogni ahvivalv tion ofover years ofservice pension fundsmgb roche connect chf chf companyincluding years fb humer member ofthe executive committee altwegg bonus paid wm burns e hunziker indirect benefits ga keller employer contributions jkc knowles made social security rt laube schemespension plans group h von prondzynski wide employee equitysharing plan villiger roche connect respect ofmem total bers ofthe executive committee shown table indirect benefits ahvivalv swiss social security programmes providing retirement disability unemployment benefits mgb stiftung der fhoffmannla roche agfr mitarbeitergewinnbeteiligung employee profit roche connecta voluntary sharing foundation supplementing occupational pension benefits equity purchase planemployees corporate governancethe opportunity buy roche non stock options voting equity securities rogis market value total value original awarded per option dec issue price amount equal oftheir annual number dec chf chf award chf salary discountnonvoting fb humer equity securities purchased altwegg plan subject holding period wm burns switzerlandfor exampleis ga keller four years jkc knowles h von prondzynski stock options villiger december members total executive committee held options tradable options purchase nonvoting equity securities issued third party issued dis awarded previous years shown tributed april securities identification exercise price swiss francs exercise inthe table stock options ratio expiry date april vesting period ends april original issue price swiss francs taxable value recipient issue date swiss francs december nonexec utive members ofthe board ofdirec tors held unvested options awarded ments securities issued peer set previous years companies operating industryparticipating executives performance share plan awarded fixed number ofnon members ofthe executive com voting equity securities mittee members oftop boards discretion cash equiva management whose performance lent end ofthe effective period major impact roches ability ofthe planperformance evalu achieve corporate objectives ated basis ofmarket price individuals worldwide partici dividend yieldsifan investment pating performance share plan roche securities outperforms established beginning peer setthe board ofdirectors ofifover period elect increase number programme effectan invest nonvoting equity securities awarded ment roche securities shares twofoldin event nonvoting equity securities outper investment roche securities forms average return invest performs average return delivered peer companiesfewer performance share plan nonvoting equity securities awardedunder provisions ofthis number nes targeted plan programme nonvoting equity securi fb humer ties reserved members wm burns executive committee set e hunziker table belowthe programme ga keller effect period ofthree years jkc knowles number ofnonvoting rt laube equity securities reserved gottlieb h von prondzynski akeller increased total ofhis increased responsibili corporate governance ties newly appointed member pensions totalling swiss francs executive committeethe number paid eight former executive ofsecurities reserved partici committee members widows pants plan remains unchanged addition benefits board ofdirectors vote received pension plans actual distribution ofsecurities plan close ofthe otherwiseno additional remunera financial reporting year tion paid current former members ofthe board ofdirectors remuneration emoluments current former members ofthe loans corporate officers executive committee daniel villiger stepped executive committee highest total remuneration requesthis remuneration chairman ofthe board ceo year detailed tables franz bhumer member heceased member ofthe roche board member ofthe pension funds december executive committee highest received portable benefit enti total remuneration shown tlement provided funds tables ruleswith respect option awards awards performance shareholdings share planthe arrangements directors andr hoffmannandreas drvilliger accorded provi oeri fritz gerber members sions ofthe applicable planshencethe ofthe founders family closely tables include awards associated belong share dr villiger entitled holder group pooled voting rights exercise end group held shares ofissued markus altwegg gottlieb akeller sharesmr gerber leave group taken mortgage loans retires board swiss francs april detailed information respectivelywith pension fund group foundin note fhoffmannla roche ltdat inter roche group consolidated est rate pathe interest rate financial statements related parties loans fixed decem notes ber financial statements ofroche holding ltd additionas fritz gerberwho served roche december nonexecutive ceo chair members ofthe board ofdirectors man ofthe roche board andpersons closely associated todoes receive benefits held sharesthe members fromany ofthe roche pension funds ofthe executive committee per receipt ofan annual sons closely associated held pension company since shares date may pension totalled swiss francs corporate governancerelationship group auditors additional information relating financial statements ofroche statutory auditors corporate governance holding ltd additional group auditors statutory auditors group structure shareholders details contained articles participate audit corporate roches operating businesses ofincorporation ofroche holding governance committee meetings organised two divisionsphar ltdwhich found auditors make written oral reports maceuticals diagnosticsthe internet wwwrochecom results oftheir auditsthe audit pharmaceuticals division comprises changes equity detailed corporate governance committee four business segments roche notes financial statements oversees assesses auditors prescriptiongenentech prescrip ofroche holding ltd makes recommendations board tionchugai prescription roche changes occurred consumer healththe diagnostics readers referred group auditorspricewaterhouse division consists offive business roches annual report coopers agreceived following areasdiabetes carenear patient company share capital remuneration services testingcentralized diagnostics swiss francsdivided molecular diagnostics applied fully paid bearer millions chf sciencebusiness activities car shares nominal value auditing services ried group subsidiaries swiss franc eachthere lim auditing groups safety associated companiesthe itations transfer ofthese environmental protection report important subsidiaries associ shares shares maximum auditrelated services ated companies listed note voting rightsupon depositshares tax consultancy services consolidated financial state voted without restric consulting services ments subsidiaries associated tions total companiespages addition nonvoting major shareholders listed note equity securities issued ernst young ltd received follow roche group consolidated bearer formthey form part ing remuneration services financial statements related ofthe share capital therefore statutory auditors ofroche holding parties notes confer voting rightseach non ltd roche financial compa financial statements voting equity security confers nies auditors ofgenentech rocheholding ltd rights one share partici chugai andr hoffmannandreas oeri pate available earnings fritz gerber serve board liquidation proceeds following chf directors representatives ofthe repayment ofthe share capital roche audits shareholders pooled voting roches nonvoting equity securities auditrelated services roche rights receive remuneration provisions securing genentech chugai audits mentioned remuneration claims rights pertaining thereto consulting services members ofthe board ofdirectors described ofthe articles provided genentech abovedr gerber additionally incorporation ofroche holding ltd chugai receives aforementioned pen information debt instruments total sionno relationships exist issued shareholders pooled standing bonds found group auditors statutory auditors voting rights note roche group elected year annual crossholdings consolidated financial statements general meeting debt capital structure information roches capital wwwrochecom company corporate structure provided notes governance articles incorporation corporate governance additional information employee science ethics advisory stock options found note group seag issues relating roche group consolidated genetics genetic engineer financial statements employee ing established stock options equity year board ofdirectors compensation benefits imposes several blackout periods roche issued options apart senior employees awarded prohibited trading com employees issued connection pany stockthe following blackout debt instruments periods effect neither options awarded january february employees debt instruments april april issued july july effect roches share capital october october blackout periods changed board directors executive chairman ofthe board ofdirec committee tors ifcircumstances warrant information member ofthe board ofdirectors held total board ofdirectors executive offive meetings committee including years management contracts elected fall within meaning years terms end subsection ofthe swx direc listed pages curricula tive information relating vitae information corporate governance board executive committee members available participatory rights shareholders wwwrochecom participatory rights ofshare internal organisation ofthe holders defined roches arti board ofdirectors division cles ofincorporationas roche ofauthority responsibilities shares issued bearerthere board management restrictions admission governed bylawsthis annual general meetingswith document published inter exception shares must net wwwrochecom deposited within specified period board ofdirectors estab date ofa meeting lished system ofcontrols admittance card must issued overseen corporate govern shareholders nameas provided ance committee consists ofthe ofthe articles ofincorpora following elements tionany shareholder elect reports financial operating represented another shareholder risks internal audits wwwrochecom company corporate compliance officer governance wwwrochecom company corporate safety environment officer governance boards bylaws corporate sustainability com wwwrochecom company corporate mittee governance articles incorporation corporate governanceat annual general meetingthe relevant information visors report com articles ofincorporation contain documentsincluding pliance officer andreas greuterdirect restrictions exercise ofvoting media releases presentations phone number rightsand quorum require analyst investor conferences disclosures treated ments stipulated areavailable english german confidentialemployees make ofthe articles ofincor internet wwwrochecom disclosures penalised porationshareholders representing publications ordered company sobut shares nominal value ofat emailfax telephone arenot immune prosecution least swiss francs baselwebmasterrochecom forlegal violations request placement ofitems tel business agenda ofan annual fax gottlieb kellerwho served general meetingthis must done contact address investor groups first compliance officer later days date relations stepped post ofthe meeting fhoffmannla roche ltdinvestor end ofhis new duties relationscorporate finance member ofthe executive commit change control defensive baselswitzerland teethe board ofdirectors named measures tel andreas greuter succeed dr keller articles ofincorporation con fax compliance officermr greuter tain provisions mandatory additional informationincluding report directly chairman bid ruleswiss law applies details specific contact persons theboard ofdirectors submit change ofcontrol isavailable wwwrochecom regular reports audit clausesthose components ofremu corporate governance committee neration based roche nonvoting nonapplicabilitynegative equity securities would termi disclosure nated event ofan acquisition expressly noted informa vesting period restrictions tion contained mentioned herein preexisting awards would nonapplicable omission removedso options construed negative disclosure could immediately exercised compliance officer information policy compliance officer committed provided ofthe articles ensuring roche corporate prin incorporationcorporate notices ciples consistently complied published schweizerisches throughout roche group also handelsamtsblatt daily serves contact person share newspapers designated board holdersemployeescustomerssuppli ofdirectors basler zeitungfinanz ers general public issues und wirtschaftlagefile temps relating implementation ofand neue zrcher zeitung compliance principles roche reports halfyear full consistent provisions year results business reports pub intent ofthe sarbanes oxley act lished print online formats section employees media conferencesin addi parties become aware ofviola tionfirst thirdquarter sales tions ofroche corporate principles figures published year bring april october attention oftheir managers super wwwrochecom investors corporate governance finance roche finance made significant progress providing solid platform value creation entrepreneurial develop ment group towards achieving conditions balanced financial income end debt reduced billion swiss francs instruments covering convertible debt obligations refinancedand shortterm bank debt replaced attractive longterm financing furthermore reduced risk expo sures financial investments foreign exchange transactions core businesses pharma diagnostics continue achieve improved operating results strong cash generationas result group net liquidity increased billion swiss francs billion swiss francs ratio equity minority interests total assets improved financefinancial review highlights millions chf roche group continuing businessesa change change local local cur cur chf rency chf rency sales ebitdab operating profit exceptional items operating profit net income continuing businesses includes core pharmaceuticals diagnostics businesses together treasury corporate activities vitamins fine chemicals division reported discontinuing business b ebitda earnings exceptional items interest financial income tax depreciation amor tisation including impairment corresponds operating profit exceptional items depreciation amortisation including impairment operating roche groups continuing businesses pharmaceuticals diagnostics showed steady progress local currency sales core businesses roughly due organic growth remainder due acquisition chugai growth local currency operating profit exceptional items driven sales growth particularly high margin products business areas reduced operating expenses operating costs increased due chugai integration launch expenses higher research develop excellent cash generation pharmaceuticals diagnostics shown ebitda billion swiss francs actively supported efforts conditions place balanced financial income end end roche group already shows significantly improved key financial figures taken additional steps improve transparency investors erich hunziker chief financial officer financial review ment expenses higher administration costs also taking account exceptional items local operating profit growth even stronger mainly result income million swiss francs genentech legal settlements second half compared charge genentech legal case city hope medical center strength swiss franc relative currencies particular us dollar thejapanese yen negative impact results example us dollar worth chf average compared chf result increase theoperating profit exceptional items groups continuing businesses translates intoa increase swiss franc terms results discontinuing vitamins fine chemicals business sold dsm effective september included groups results first nine months groups operating profit including vitamins fine chemicals increased billion swiss francs billion swiss francs increase drivers positive results core businesses partially offset impacts divest ment vitamins fine chemicals business notably impairment charge million swiss francs loss divestment million swiss francs results included million swiss francs expenses vitamin case million swiss francs vitamins fine chemical business impairment treasury financing significant progress made towards achieving conditions balanced financial income end roche showing improved financial strength steps taken include restructuring reduction groups debt refinancing instruments covering convertible debt obligations reduction financial risk exposures achievements principally based strong cash generation operating business major items like proceeds sale vitamins fine chemicals business dsm addition debt significantly reduced bank loans switched capital market debt bullet lyons ii debt instruments repaid total cash outflow billion swiss francs conversion helveticus bonds reduced debt million swiss francs first issues european medium term note programme raised proceeds billion swiss francs attractive conditions used refinance existing shortterm bank debt longterm capital market financing group net liquidity increased billion swiss francs billion swiss francs group reassessed refinanced instruments cover potential conversion obligations may arise convertible debt instruments december group reclassified forward purchases nonvoting equity securities equity debt thiswas done based developments international accounting lyons ii convertible bond redeemed freedup nonvoting equity securities covering potential conversion obligation partly used disetronic acquisition partly sold proceeds used close forward purchases potential conversion obligation lyons v sumo convertible bonds covered low exercise price options future cash commitments classified equity rather debt result transactions group stronger transparent balance sheet closing forward purchases reduced interest expenses longterm debt december longterm debt reduced billion swiss francs financial longterm assets reduced billion swiss francs net cash outflow billion swiss francs additional details given note consolidated financial statements financial reviewthe financial risk exposures decreased proportion financial assets heldin equities reduced net adverse effect net income equity securities amount billion swiss francs total cash marketable securities compared billion swiss francs end total cash marketable securities market risk financial assets measured using valueatrisk var model indicates confidence next month potential loss asset value exceed million swiss francs impairment charges financial assets million swiss francs million swiss francs arose shares experienced large falls second half failed recover sufficiently following six months groups impairment threshold impairments second half million swiss francs foreign exchange risks also reduced profits continuously increasingly lockedin upon favourable movements exchange rates thereby reducing foreign exchange transaction exposures according valueatrisk analysis confidence potential foreign exchange loss next month exceed million swiss francs roche shows significantly improved balance sheet healthy risk profile operating results continuing business exceptional items millions chf sales core business sales grew local currencies swiss francs roche group recorded sales billion swiss francs two core businesses represents increase local currencies swiss francs approximately increase due organic growth due integration ofchugai growth driven pharmaceuticals division rate sales growth increased significantly reaching local currencies swiss francs thediagnostics division posted increase local currencies swiss francs change change local chf currencies pharmaceuticals total prescription roche prescriptiona genentech prescription chugai prescriptionb otcc diagnostics sales continuing businesses sales exclude nippon roche prescription classified part chugai prescription segment b sales consist chugai prescription nippon roche prescription c consists roche otc chugai otc financial review operating profit substantial growth profitability increase operating profit exceptional items continuing businesses excludes results vitamins fine chemicals division increased local currencies swiss francs billion swiss francs growth driven increased sales lower operating expenses development partially offset increased operating costs primarily result chugai integration also investments marketing new products pegasys fuzeon activities supporting development pipeline newly inlicensed andoptin compounds operating profit exceptional items margin increased percentage points percent sales change change local chf currencies sales cost sales gross profit marketing distribution research development administration amortisation intangible assets operating income operating expenses operating profit continuing businesses exceptional items gross profit increased swiss francs billion swiss francs compared gross profit margin remained stable reflects strong growth inhighmargin prescription products effects continuing productivity improvements compensated lower average gross profit margin chugai disetronic acquisition accounting integration impacts marketing distribution increased swiss francs billion swiss francs increase driven support newly launched products pegasys copegus fuzeon geographic rollout well prelaunch launch activities genen tech xolair raptiva avastin chugai renagel xeloda pegasys group level acquisition chugai contributed local growth marketing distribution percentage sales remained fairly stable around research development increased swiss francs billion swiss francs tosupport strong research development pipelines pharmaceuticals diagnostics including inlicensed optin compounds group level acquisition chugai con tributed roughly local growth research development costs percentage sales group level reached level valid pharmaceuticals accounts almost group 's research development expenses reached sales diagnostics reached financial reviewadministration increased swiss francs billion swiss francs group level acquisition chugai contributed around local growth remainder primarily driven genentech acquisition disetronic amortisation intangible assets increased swiss francs billion swiss francs amortisation intangible assets chugai acquisition million swiss francs compared million swiss francs fourth quarter dise tronic since may million swiss francs operating income increased swiss francs billion swiss francs pri marily second half gain million swiss francs disposal neupogen compensated second half gain million swiss francs million us dollars sale protein design labs exclusive worldwide rights market develop sell zenapax disease indications organ transplantation first half litigation settlement income bayer operating expenses decreased swiss francs billion swiss francs reduction primarily due million swiss francs lower foreign exchange losses receivables latin america turkey due recovery corresponding currencies million swiss francs lower restructuring expenses million swiss francs lower sap implementation costs lower impairment charges partially offset higher royalty expenses divisional results continuing business exceptional items millions chf operating operating profit ebitda profit exceptional sales exceptional items third parties ebitda sales items sales pharmaceuticals total prescription roche prescription genentech prescription chugai prescription otc diagnostics group total continuing businesses financial review operating operating profit ebitda profit exceptional sales exceptional items third parties ebitda sales items sales pharmaceuticals total prescription roche prescription genentech prescription chugai prescription otc diagnostics group total continuing businesses pharmaceuticals sales pharmaceuticals division reached billion swiss francs increase local currencies swiss francs ebitda totalled billion swiss francs inlocal currencies swiss francs margin remained fairly stable sales operating profit exceptional items increased local currencies swiss francs billion swiss francs margin rose higher operating profitability driven sales growth spite considerably increased spending new products scheduled launches support existing products particularly neorecormon strong research development pipeline operat ing income operating expenses declined parallel income side gain sale zenapax rights protein design labs partially compensated gain onneupogen expense side decline particular due absence restructuring expenses million swiss francs million swiss francs impairment charge relating tothe pharmaceuticals division restructuring lower foreign exchange losses receivables inlatin america turkey total prescription local currency sales prescription medicines rose billion swiss francs swiss francs growth driven roches successful oncology products products contributing strong sales growth included pegasyscopegus neorecormon cellcept sales antibiotic rocephin remained stable continued high demand italy growth us compensated generic competition europe particular france germany acne medicine roaccutaneaccutane declined local terms due tighter us prescription requirements generic competition us europe xeni cal sales decreased line market trends roche prescription business improved operating profit exceptional items percent sales percentage points due increased gross profit margin lower operating expenses increased gross profit margin partially result additional manufacturing validations start scaleup costs pegasys fuzeon increased regulatory compliance costs lower operating expenses primarily due significantly lower foreign exchange losses receivables costs relating pharmaceuticals division restructuring positive effects partially offset increased marketing efforts newly launched products pegasyscopegus fuzeon increased costs strong research development pipeline genentech prescription business continued strong sales profit growth ebitda margin increased primarily result increased sales financial reviewat higher gross profit margin due economies scale production due milestone payment research collaboration partner ebitda margin genentech prescription business underlines strong contribution groups operating cash generation chugai prescription business posted operating profit exceptional items million swiss francs ebitda margin compared development driven higher sales improved gross profit margin positive effects chugais restructuring programme combined effect million swiss francs final writeoff remaining fair value adjustments inventories result acquisition accounting million swiss francs restructuring expenses recorded roughly level writeoff fair value adjustments inventories million swiss francs otc sales nonprescription medicines rose local currencies swiss francs billion swiss francs roche consumer health sales excluding chugai grew local currencies billion swiss francs due strong growth markets especially asiapacific eastern europe driven bepanthen redoxon aleve otc operating profit exceptional items totalled million swiss francs growing local currencies swiss francs compared operating profit exceptional itemsmargin declined percentage points sales decline driven thelower profitability chugais otc business investments develop orlistat xenical asan otc product diagnostics sales increased local currencies swiss francs twice fast theworldwide market invitro diagnostics billion swiss francs growth driven profitable business areas namely diabetes care invitro diagnostics business molecular diagnostics immunodiagnostics business centralized diagnostics downturn biotech research negatively impacted growth rates applied science divestment ofthe nonclinical drugofabusetesting business opti product lines negatively impacted growth rate near patient testing diagnostics level sales growth impacts divestments offset acquisition disetronic exceptional items oper ating profit increased local currencies swiss francs billion swiss francs ebitda swiss francs billion swiss francs profitability improved operating profit ebitda margins percentage points sales respectively higher marketing spend rising research development expenses forthe broadest research development pipeline industry higher amor tisation intangible assets result disetronic acquisition offset reduced sap implementation costs gains continuing product portfolio asset realignments litigation settlement income bayer result consists costs corporate headquarters discontinuing operations millions chf sales operating profit exceptional items vitamins fine chemicals business effective september receiving final regulatory approvals group completed sale global vitamins fine chemicals business dutch company dsm results roche group include results vitamins fine chemicals business september financial review exceptional items millions chf continuing businesses discontinuing businesses group operating profit exceptional items amortisation goodwill major legal cases changes group organisation operating profit amortisation goodwill remained stable billion swiss francs although increased inlocal currencies goodwill amortisation chugai acquisition accounting million swiss francs compared million swiss francs addition million swiss francs goodwill amortisation disetronic acquisition may following implementation recent accounting changes companies using accounting princi ples generally accepted united states us gaap longer amortise goodwill required perform impairment test least annually roche continues amortise goodwill including held genentech required international financial reporting standards ifrs presents exceptional item view proposed ifrs changes improve comparability healthcare peers major legal cases million swiss francs income due cash received million swiss francs litigation settlements genentech second half year net expense million swiss francs resulting judgement igen litigation issued july million swiss francs provision recorded genentech legal case city hope medical center changes group organisation net proceeds received dsm billion euros billion swiss francs include provisional deduction agreed price adjust ment mechanisms mainly related cashanddebtfree basis working capital levels vitamins fine chemicals business final amounts arising mechanisms including net debt calculation subject review approval group dsm andare therefore liable change taking account incidental transaction costs residual obligations retained roche group preliminary assessment made september showed additional loss disposal million swiss francs arose disposal vitamins fine chemicals business addition impair ment charge million swiss francs recorded first half final assessment made following review approval group dsm income million swiss francs recognised chugai transaction impairment charge million swiss francs recorded vitamins fine chemicals business operating profit major impact exceptional items operating profit continuing businesses increased local currencies swiss francs billion swiss francs higher growth compared growth local currencies swiss francs operating profit exceptional items mainly result oneoff income million swiss francs genentech legal settlements second half compared charge genentech legal case city hope medical center financial reviewincome associated companies millions chf continuing businesses discontinuing businesses group income associated companies result associates significant major impacts coming basilea financial income millions chf continuing businesses discontinuing businesses group financial income exceptional impairment financial assets financial income decreased net expense million swiss francs net income million swiss francs however comparative result includes gain million swiss francs labcorp transactions excluding gain financial income anet expense million swiss francs net income equity securities loss million swiss francs result includes impairment charges million mainly relating equity securities december market value groups impairment threshold less sustained sixmonth period excluding impairment charges income million swissfrancs achieved equity securities interest income million swiss francs adecrease relative prior year caused lower holdings debt securities falls interest rates interest expense reduced million swiss francs mainly due reduction restructuring debt fall interest rates less impact interest rates large parts debt fixed group achieved net foreign exchange gains million swiss francs profits continuously increasingly lockedin upon favourable movements exchange rates full breakdown financial income given note consolidated financial statements income taxes millions chf continuing businesses discontinuing businesses group profit taxes income taxes profit taxes groups continuing businesses effective tax rate remained stable year despite increasing profit contribution genentech chugai higher tax rates groups overall effective tax rate due tax effects vitamins fine chemi cals disposal groups effective tax rate continuing businesses exceptional items full reconciliation tax charge given note consolidated financial statements financial review minority interests millions chf continuing businesses discontinuing businesses group minority interests income applicable minorities increased mainly due continually improving profit contribu tion genentech impact genentech legal cases cause swing million swiss francs million swiss francs income applicable minorities relates genentech million swiss francs relates chugai net income millions chf continuing businesses discontinuing businesses group net income earnings per share nonvoting equity security basic chf diluted chf group returned profit large exceptional charges incurred netincome includes first full year chugai group net income still includes nine months results vitamins fine chemicals business well additional impairments net assets loss disposal cash flows net liquidity millions chf cash flow statement cash generated business operations net cash inflow outflow major legal cases operating cash flows operating activities income taxes income taxes paid activities operating activities financing activities investing activities net effect currency translation cash increase decrease cash financial reviewoperating cash flows groups operations continued show strong cash generation business operations billion swiss francs driven continued growth ebitda cash flows operating activities improved greatly compared period due lower vitamin case payments inclusion billion swiss francs payment collateral account relation igen litigation reversed net inflow billion swiss francs also much lower net cash outflow income taxes large income tax receivables recorded end recovered tax authorities financing cash flows significant financing cash flows dividend payment billion swiss francs billion swiss francs repayment bullet bonds lyons ii notes billion swiss francs proceeds three issues groups european medium term note programme refinanced existing shortterm debt refinancing instruments covering convertible debt obligations resulted cash outflow billion swiss francs see note consolidated financial statements investing cash flowsthe significant cash flows proceeds billion swiss francs divestment vitamins fine chemicals business consists billion swiss francs received dsm net billion swiss francs cash held divested companies investing cash flows also include increased expenditure property plant equipment intangible assets net cash outflow groups portfolio marketable securities order fund purchase disetronic debt repayments vitamin case payments net liquidity december december cash marketable securities financial longterm assets derivative financial instruments net equity instruments financial assets longterm debt shortterm debt total debt net liquidity net liquidity increased outflows dividend payment acquisition ofdisetronic covered strong cash flows operating activities funds received divestment vitamins fine chemicals business financial review various debt instrument transactions affect debt cash therefore net effect lyons iii lyons iv notes total book value billion swiss francs reclassified shortterm longterm debt redeemable option group may january respectively balance sheet millions chf december december change longterm assets current assets total assets equity minority interests noncurrent liabilities current liabilities total equity minority interests liabilities longterm assets sale vitamins fine chemicals business reduced property plant equipment billion swiss francs billion swiss francs collateral account relation igen litigation repaid group lowering financial longterm assets theacquisition disetronic increased goodwill intangible assets billion swiss francs financial longterm assets reduced billion swiss francs collateral supporting instruments covering convertible debt obligations released current assets sale vitamins fine chemicals business also impact current assets notably reducing inventories billion swiss francs equity significant movements net income billion swiss francs billion swiss francs dividend payment minority interests increase driven improving performance genentech cur rency translation effects noncurrent liabilities proceeds european medium term note programme increased longterm debt billion swiss francs lyons iii lyons iv notes book value billion swiss francs classified shortterm debt refinanc ing instruments covering convertible debt obligations reduced longterm debt billion swiss francs current liabilities repayment bullet bonds lyons ii notes decreased short term debt billion swiss francs vitamin case payments billion swiss francs reduced shortterm provisions reclassification lyons iii lyons iv notes book value billion swiss francs increased current liabilities financial reviewfinancial risks foreign exchange risk group operates across world exposed movements foreign currencies affecting net income financial position expressed swiss francs local local currencies currencies chf chf growth continuing businesses sales operating profit exceptional items december average december average exchange rates swiss franc usd eur gbp jpy average swiss franc stronger us dollar japanese yen weaker euro total negative currency effect sales growth continuing businesses operating profit growth points absolute terms sensitivity group sales continuing businesses change us dollar swiss franc swiss francs average approximately million swiss francs corresponding sensitivities euro yen approximately million swiss francs million swiss francs respectively group monitors net currency exposures appropriate enters transactions aim preserving value assets commitments anticipated transactions group uses forward contracts swaps foreign currency options optimise certain anticipated foreign exchange revenues cash flows financing transactions group pursued astrategy continuously lockin favourable developments foreign exchange rates entering derivative contracts thereby reducing exposure potential future moves foreign exchange rates result groups overall transaction risk decreased continuously transaction risk monetary positions quantified using valueatrisk var approach measures potential negative impact foreign exchange results due adverse changes inforeign exchange rates var calculation based normal market condi tions confidence level holding period days december december foreign exchange risks millions chf change var monetary positions interest rate risk interest rate risk arises movements interest rates could adverse effects thegroups net income financial position changes interest rates cause variations interest income expenses interestbearing assets liabilities addition affect market value certain financial assets liabilities instruments group manages interest rate risk necessary using financial derivatives swaps options financial review group pursued goal reducing debt consequence exposure potential changes interest rates decreased continuously interest rate var measuring thepotential change net market value interest rate sensitive assets liabilities con tinuously declined potential increase interest expenses due movements interest rates material group major debt instruments fixed interest rates group level potential impacts interest rate changes financial instruments monitored quan tified using valueatrisk var earningsatrisk ear models var measures potential change fair value interest sensitive financial instruments ear reflects potential change net annual interest expenses could result adverse interest rate movements var ear measured using historical simulation approach normal market conditions aconfidence level holding period days december december interest rate risks millions chf change var instruments sensitive interest rates ear instruments sensitive interest rates market risk financial assets changes market value cash marketable securities affect net income financial position group market risk arises movements stock prices interest rates foreign exchange rates group decided change risk profile reducing equity position considerably equity securities amount billion swiss francs billion swiss francs total cash marketable securities continuous shift groups asset allocation resulted reduction var throughout year market risk measured using valueatrisk var model based confidence level holding period days excludes positions genentech chugai run treasury operations independently thus var represents expected level loss exceeded probability following days december december market risk financial assets millions chf change var cash marketable securities valueatrisk earningsatrisk analysis tools valueatrisk var calculations used indicate within ranges value respective assets liabilities may fluctuate certain probability certain time period holding period var measure statistical measure implicitly assuming value changes recent past indicative value changes future market shocks included calculation unless recently observed group conducts additional stress test ing take possibilities consideration group uses statistically relevant observation periods applies holding periods reflect time period required change respec tive risk exposure deemed appropriate longer holding periods probability higher value changes increases var measure financial reviewearningsatrisk ear equivalent var methodology rather potential value changes indicates potential changes profits losses certain probability acertain time period constraints limitations apply methodology var ear models based historical simulation approach simulates effects historical price rate movements current positions historical scenario representing price rate changes individual instruments specific day period past financial instruments fully revalued using valuation models total change value earnings determined group predict future market movements var ear figures given notrepresent actual losses expected might incurred financial assets liabilities possible worst loss period stated consider effect favourable changes market rates financial review roche group consolidated financial statements reference numbers indicate corresponding notes consolidated financial statements consolidated income statement millions chf continuing discontinuing businesses businesses group sales cost sales gross profit marketing distribution research development administration amortisation intangible assets operating income operating expenses operating profit exceptional items amortisation goodwill major legal cases changes group organisation operating profit income associated companies financial income profit taxes income taxes profit taxes minority interests net income earnings per share nonvoting equity security basic chf diluted chf roche group consolidated financial statementsconsolidated income statement millions chf continuing discontinuing businesses businesses group sales cost sales gross profit marketing distribution research development administration amortisation intangible assets operating income operating expenses operating profit exceptional items amortisation goodwill major legal cases changes group organisation operating profit income associated companies financial income exceptional impairment financial assets profit taxes income taxes profit taxes minority interests net income earnings per share nonvoting equity security basic chf diluted chf sales marketing distribution expenses reduced million swiss francs due reclassification cash discounts see note roche group consolidated financial statements consolidated balance sheet millions chf december december longterm assets property plant equipment goodwill intangible assets investments associated companies financial longterm assets deferred income tax assets longterm assets total longterm assets current assets inventories accounts receivable current income tax assets current assets marketable securities cash cash equivalents total current assets total assets equity share capital nonvoting equity securities genussscheine pm pm equity instruments retained earnings fair value reserves total equity minority interests noncurrent liabilities longterm debt deferred income tax liabilities liabilities postemployment benefits provisions noncurrent liabilities total noncurrent liabilities current liabilities shortterm debt current income tax liabilities provisions accounts payable accrued current liabilities total current liabilities total equity minority interests liabilities pm pro memoria nonvoting equity securities nominal value see note roche group consolidated financial statementsconsolidated statement changes equity millions chf year ended december share capital balance january december nonvoting equity securities genussscheine balance january december pm pm equity instruments balance january acquisition disetronic conversion helveticus bonds refinancing instruments covering convertible debt obligations movements year reclassification obligations repurchase equity instruments balance december retained earnings balance january net income dividends paid balance december fair value reserves balance january increase decrease fair value income expense recognised income statement deferred income taxes minority interests currency translation gains losses balance december total equity december pm pro memoria nonvoting equity securities nominal value see note roche group consolidated financial statements consolidated cash flow statement millions chf year ended december cash flows operating activities cash generated operations increase decrease working capital vitamin case payments igen litigation genentech legal cases payments made defined benefit postemployment plans restructuring costs paid utilisation provisions operating cash flows cash flows operating activities income taxes paid income taxes paid total cash flows operating activities cash flows financing activities proceeds issue longterm debt instruments repayment longterm debt instruments increase decrease longterm debt refinancing instruments covering convertible debt obligations transactions equity instruments increase decrease shortterm borrowings interest dividends paid genentech chugai stock repurchases exercised employee stock options genentech financing cash flows total cash flows financing activities cash flows investing activities purchase property plant equipment purchase intangible assets disposal property plant equipment disposal intangible assets disposal products acquisitions subsidiaries associated companies divestments subsidiaries associated companies proceeds sale labcorp shares interest dividends received sales purchases marketable securities net investing cash flows total cash flows investing activities net effect currency translation cash increase decrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year consisting cash cash equivalents roche group consolidated financial statementsnotes roche group consolidated financial statements reference numbers indicate corresponding notes consolidated financial statements summary significant accounting policies basis preparation consolidated financial statements consolidated financial statements roche group prepared accordance international financial reporting standards ifrs including standards interpretations issued international accounting standards board iasb prepared using historical cost convention except disclosed accounting policies certain items including derivatives availableforsale investments shown fair value approved issue board directors february preparation consolidated financial statements requires management make estimates assumptions affect reported amounts revenues expenses assets liabilities disclosure contingent liabilities date financial statements future estimates assumptions based managements best judgement date financial statements deviate actual circumstances original estimates assumptions modified appropriate year circumstances change necessary comparatives reclassified extended previously reported results take account presentational changes group changed presentation income statement financial statements current year comparative results split continuing discontinuing businesses impairment longterm assets costs pharmaceuticals division restructuring classified part operating expenses amortisation goodwill intangible assets presented separately operating income operat ing expenses income associated companies presented part profit taxes done order show better comparability results healthcare companies allow readers make clearer assessment sustainable earnings capacity group results reclassified new format operating profit netincome earnings per share unchanged previously reported results consolidation policy financial statements consolidated financial statements roche holding ltd acompany registered switzerland subsidiaries group subsidiaries companies controlled directly indirectly roche holding ltd control defined power govern financial operating policies enter prise obtain benefits activities control normally evidenced roche holding ltd owns either directly indirectly voting rights potential vot ing rights companys share capital special purpose entities consolidated sub stance relationship special purpose entity controlled group companies acquired year consolidated date operating control transferred group subsidiaries divested included date control passes notes roche group consolidated financial statements group companies acquired exclusively resold near future consoli dated classified assets held sale carried fair value intercompany balances transactions resulting unrealised income eliminated full investments associated companies accounted equity method com panies group exercises significant influence control isnormally evidenced group owns voting rights potential voting rights company balances transactions associated companies result un realised income eliminated extent groups interest associated company interests joint ventures reported using linebyline proportionate consolidation method segment reporting groups primary format segment reporting business segments secondary format geographical segments risks returns groups operations primarily deter mined different products group produces rather geographical location groups operations reflected groups divisional management organisational structure groups internal financial reporting systems group two divisions pharmaceuticals diagnostics disposal september group third division vitamins fine chemicals within pharmaceuticals division four subdivisions roche prescription genentech prescription chugai pre scription consumer health otc four subdivisions separate management reporting structures within pharmaceuticals division considered separately reportable segments certain corporate activities reasonably allocated reportable segments costs corporate headquarters reported others thegroups geographical segments determined geographical location similarity economic envi ronments transfer prices business segments set arms length basis divisional assets liabilities consist property plant equipment goodwill intangible assets trade receivablespayables inventories segment assets liabilities consist assets liabilities reasonably attributed reported business segments include pension assetsliabilities provisions nonsegment assets liabilities mainly include current deferred income tax balances financial assets liabilities principally cash marketable securities investments debt capital expenditure com prises additions goodwill intangible assets additions property plant equipment including arising acquisitions foreign currency translation group companies use local currency measurement currency certain group companies use currencies namely us dollars swiss francs euros measurement currencies usefully represents results financial positions com panies given local economic conditions circumstances local transactions curren cies initially reported using exchange rate date transaction gains losses settlement transactions gains losses translation monetary assets liabilities denominated currencies included income except qualifying cash flow hedges deferred equity notes roche group consolidated financial statementsupon consolidation assets liabilities group companies using measurement currencies swiss francs foreign entities translated swiss francs using yearend rates exchange sales costs expenses net income cash flows translated average rates exchange year translation differences due changes exchange rates beginning end year difference net income translated average yearend exchange rates taken directly equity divestment foreign entity identified cumulative currency translation differences relating foreign entity recognised income part gain loss divestment revenues cost sales sales represent amounts received receivable goods supplied customers deducting trade discounts cash discounts volume rebates excluding sales value added taxes revenues sale products recognised upon transfer customer significant risks rewards usually upon shipment revenues recorded earned services performed cost sales includes corresponding direct production costs related production overhead goods manufactured services rendered startup costs vali dation achievement normal production capacity expensed incurred royalty income recognised accrual basis accordance economic substance agreement reported part operating income research development research costs charged income incurred development costs capitalised intangible assets probable future economic benefits flow group intangible assets amortised straightline basis period expected benefit reviewed impairment balance sheet date development costs charged income incurred since criteria recognition asset met inlicensing milestone upfront receipts payments certain group companies notably genentech receive thirdparties upfront milestone similar nonrefundable payments relating sale licensing products technology revenue associated performance milestones recognised based achievement milestones defined respective agreements revenue nonrefundable upfront pay ments licence fees initially reported deferred income recognised income earned period development collaboration manufacturing obligation pay ments made group companies third parties associated companies items charged income research development costs unless probable future eco nomic benefits flow group normally evidenced regulatory approval case capitalised development costs amortised described practice means inlicensing milestone payments pharmaceutical products expensed incurred cases yet gained regulatory approval receipts pay ments consolidated subsidiaries genentech chugai roche group subsidiaries eliminated consolidation except extent impacts minority interests notes roche group consolidated financial statements employee benefits wages salaries social security contributions paid annual leave sick leave bonuses nonmonetary benefits accrued year associated services rendered employees group group provides longterm employee benefits cost accrued match rendering services employees concerned group operates number defined benefit defined contribution plans throughout world cost year defined benefit plans determined using projected unit credit method reflects service rendered employees dates valuation incorporates actuarial assumptions primarily regarding discount rates used determining present value benefits projected rates remuneration growth longterm expected rates return plan assets discount rates based market yields highquality corporate bonds country concerned differences assumptions actual experiences effects changes actuarial assumptions allocated estimated average remaining working lives employees differences exceed defined corridor past service costs allocated average period benefits become vested pension assets liabilities different defined benefit schemes offset unless group legally enforceable right use surplus one plan settle obligations plan pension assets recognised extent group able derive future economic benefits way ofrefunds plan reductions future contributions groups contributions defined contribution plans charged income statement year relate group operates several equity compensation plans including separate plans genentech chugai fixed plans roche option plan equivalent plans genen tech chugai expense recognised date issue exercise price greater equal fair value underlying equity instrument date issue subsequent cash flows exercises vested grants recorded equity case genentech chugai plans balance sheet minority interests performance related variable plans roche performance share plan stock appreciation rights expense accrued vesting period difference exercise price fair value ofthe underlying equity instrument group discloses values issued options using blackscholes option valuation model blackscholes model developed traded options vesting transfer restrictions since various plans used group include restrictions fair value options issued would lower unadjusted value implied blackscholes methodology taxation income taxes include taxes based upon taxable profits group including withholding taxes payable distribution retained earnings within group taxes based onincome property capital taxes included within operating expenses financial income according nature provision income taxes mainly withholding taxes could arise remittance retained earnings principally relating subsidiaries made current inten tion remit earnings notes roche group consolidated financial statementsdeferred income taxes provided using liability method temporary differences tax bases assets liabilities carrying amounts financial statements deferred income tax assets relating carryforward unused tax losses recognised extent probable future taxable profit available unused tax losses utilised current deferred income tax assets liabilities offset income taxes levied taxation authority legally enforceable right offset deferred income taxes determined based currently enacted tax rates applicable tax jurisdiction group operates property plant equipment property plant equipment initially recorded cost purchase construction depreciated straightline basis except land depreciated estimated useful lives major classes depreciable assets follows buildings land improvements years machinery equipment years office equipment years motor vehicles years investment grants similar assistance projects initially recorded deferred income inother noncurrent liabilities subsequently recognised income useful lives related assets repairs maintenance costs recognised expenses incurred borrowing costs capitalised leases leases property plant equipment group substantially risks rewards ownership classified finance leases finance leases capitalised start lease fair value present value minimum lease payments lower rental obligation net finance charges included debt assets acquired finance leases depreciated accordance groups policy property plant equipment interest element finance cost charged income lease term leases substantially risks rewards ownership transferred group classified operating leases payments made operating leases charged income straightline basis period lease notes roche group consolidated financial statements business combinations goodwill business combinations accounted using purchase method accounting cost acquisition cash paid plus fair value date exchange purchase con sideration given exchange control net assets acquired company cost acquisition also includes directly attributable incidental costs acquired identifiable assets liabilities initially recognised fair value group acquire ership acquired company assets liabilities recognised fair value extent groups interest minority interest recorded minoritys proportion pre acquisition carrying amounts acquired assets liabilities goodwill recorded surplus cost acquisition groups interest fair value identifiable net assets acquired goodwill fair value adjustments recorded assets liabilities acquired company recorded local currency company goodwill amortised useful life straightline basis estimated useful life goodwill years goodwill may also arise upon investments associated companies surplus cost investment initial value investment applying equity method goodwill recorded within investments associated companies amortisation included within income associated companies intangible assets patents licences trademarks intangible assets initially recorded fair value assets acquired business combination fair value allocated acquisition accounting acquired business combination initial fair value cost intangible assets amortised useful lives straightline basis estimated useful life lower legal duration economic useful life maximum years impairment nonmonetary assets evidence asset may impaired recoverable amount asset calculated impairment assessment carried recoverable amount asset higher net selling price value use less carrying amount carrying amount reduced recoverable value reduction reported income statement impairment loss value use calculated using estimated cash flows generally fiveyear period extrapolating projections subsequent years discounted using appropriate longterm pretax interest rate impairment loss arises useful life asset question reviewed necessary future depreciationamortisation charge accelerated impairment financial assets discussed financial assets policy inventories inventories stated lower cost net realisable value cost finished goods work process comprises raw materials direct labour directly attributable costs overheads based upon normal capacity production facilities borrowing costs included cost determined using weighted average method net realisable value estimated selling price less cost completion selling expenses notes roche group consolidated financial statementsaccounts receivable accounts receivable carried original invoice amount less allowances made doubt fulaccounts allowance recorded difference carrying amount recoverable amount objective evidence group able collect allamounts due cash cash equivalents cash cash equivalents comprise cash hand time call current balances banks similar institutions readily convertible known amounts cash subject insignificant risk changes value maturity three months less date acquisition definition also used cash flow statement equity instruments groups holdings equity instruments recorded deduction equity original cost acquisition consideration received subsequent resale equity instru ments movements reported changes equity instruments acquired primarily meet obligations may arise respect certain groups debt instruments december group revised classification obligations repurchase equity instruments based developments international practice exposure drafts pro posed changes ifrs published iasb reclassified liabilities measured present value final obligation discounted using appropriate longterm pretax interest rate discussed note positions refinanced obligations remaining december debt instruments debt instruments initially reported cost proceeds received net transaction costs subsequently reported amortised cost using effective interest method extent debt instruments hedged qualifying fair value hedges carrying value hedged item adjusted fair value movement attributable risk hedged discount net proceeds received principal value due redemption amortised duration debt instrument recognised part interest expense income statement issue convertible debt instruments cost liability portion initially calculated using market interest rate equivalent nonconvertible instrument remainder net proceeds allocated equity conversion option reported equity deferred income tax liabilities equity conversion option shares consolidated subsidiary portion net proceeds attributable option recorded within minority interest liability element subsequently reported amortised cost amortisation debt discount release deferred tax liabilities recognised income statement duration debt instrument value equity conversion option recorded equity changed future periods limited conversion preferred stock substance financial liability rather equity instrument therefore classified longterm debt balance sheet related dividend payments treated interest expense notes roche group consolidated financial statements provisions provisions recognised legal constructive obligation incurred probably lead outflow resources reasonably estimated provisions recorded estimated ultimate liability expected arise taking account foreign currency effects time value money material contingent liability disclosed existence obligation confirmed future events amount obligation measured reasonable reliability contingent assets recognised disclosed inflow economic benefits probable fair values fair value amount financial asset liability instrument could exchanged knowledgeable willing parties arms length transaction determined reference quoted market prices adjusted estimated transaction costs would incurred actual transaction use established estimation techniques option pricing models estimated discounted values cash flows fair values balance sheet date approximately line reported carrying values unless specifically mentioned notes consolidated financial statements financial assets financial assets principally investments including marketable securities classified either heldfortrading availableforsale heldtomaturity originated group heldfor trading financial assets acquired principally generate profit shortterm fluctuations price heldtomaturity financial assets securities fixed maturity group intent ability hold maturity financial assets originated group loans longterm financial assets created group acquired issuer primary market financial assets considered availableforsale financial assets initially recorded cost including transaction costs purchases sales recognised settlement date heldfortrading financial assets subsequently carried fair value changes fair value recorded financial income period inwhich arise heldtomaturity financial assets subsequently carried amortised cost using effective interest rate method availableforsale financial assets subsequently carried fair value unrealised changes fair value recorded equity avail ableforsale financial assets sold impaired otherwise disposed cumulative gains losses previously recognised equity included financial income current period financial assets originated group subsequently carried amortised cost financial assets assessed possible impairment balance sheet date impairment charge recorded objective evidence impairment issuer bankruptcy default significant financial difficulty financial assets carried amor tised cost impairment charge difference carrying value recover able amount calculated using estimated future cash flows discounted using appropriate longterm pretax interest rate availableforsale financial assets impairment charge amount currently carried equity difference original cost net previous impairment fair value notes roche group consolidated financial statementsas december group revised accounting estimates impairment financial assets based developments international practice exposure drafts proposed changes ifrs published iasb addition impairment triggers availablefor sale financial assets market value original cost net previous impairment sustained sixmonth period considered impaired decreases market price less original cost net previous impairment orfor less sustained sixmonth period considered objective evidence impairment movements fair value recorded equity isobjective evidence impairment asset sold otherwise disposed derivatives derivative financial instruments initially recorded cost including transaction costs derivatives subsequently carried fair value apart derivatives designated qualifying cash flow hedging instruments see changes fair value recorded asfinancial income period arise hedging purposes hedge accounting hedging relationships may three types fair value hedges hedges particular risks may change fair value recognised asset liability cash flow hedges hedges particular risks may change amount timing offuture cash flows hedges net investment foreign entity hedges particular risks may change carrying value net assets foreign entity qualify hedge accounting hedging relationship must meet several strict conditions documentation probability occurrence hedge effectiveness reliability measurement conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently nohedging relationship particular derivatives reported fair value changes fair value included financial income qualifying fair value hedges hedging instrument recorded fair value hedged item recorded previous carrying value adjusted changes fair value attributable hedged risk changes fair values reported financial income qualifying cash flow hedges hedging instrument recorded fair value portion ofany change fair value effective hedge included equity remaining ineffective portion reported financial income hedging relationship hedge firm commitment highly probable forecasted transaction cumulative changes offair value hedging instrument recorded equity included initial carrying value asset liability time recognised qualifying cash flow hedges cumulative changes fair value hedging instrument recorded equity included financial income time forecasted transaction affects net income qualifying hedges net investment foreign entity hedging instrument recorded fair value portion change fair value effective hedge included equity remaining ineffective portion recorded financial income hedging instrument derivative equity cases entity disposed cumulative changes fair value hedging instrument recorded equity included financial income time disposal notes roche group consolidated financial statements changes accounting policy line developing international practice cash discounts classified deduction sales previously cash discounts reported marketing distribution expenses comparative figures financial statements sales marketing distribution expenses reduced million swiss francs impact operating profit net income reclassification comparative segment discontinuing operations information also restated international financial reporting standards revised new standards interpretations became effective january significant effect groups financial statements late inter national accounting standards board published revised version ias financial instruments disclosure presentation revised version ias financial instruments recognition measurement improvements international accounting standards whichmakes changes existing standards must adopted possible early adoption group currently assessing potential impacts new standards several exposure drafts also published notably ed sharebased payment ed business combinations final standards expected early financial risk management financial risk management within group governed policies guidelines approved senior management policies guidelines cover foreign exchange risk interest rate risk market risk credit risk liquidity risk group policies guidelines also cover areas cash management investment excess funds raising short longterm debt group companies report details financial instruments outstanding financial liquidity togroup treasury least monthly basis groups subsidiaries genentech chugai treasury operations operational independence whilst working within afinancial risk management framework consistent rest group com pliance groups financial risk management policies guidelines overseen financial risk manager group accordance risk management guidelines continues monitor risks deemed appropriate certain risks significantly altered use financial instruments derivatives group management believes order create optimum value group desirable eliminate mitigate possible market fluctuations group engage financial transactions trading speculative pur poses shortterm positions sometimes entered take advantage market opportunities asset management foreign exchange risk group operates across world exposed movements foreign currencies affect ingits net income financial position expressed swiss francs group continues monitor currency exposures appropriate enters transactions aim preserving value assets commitments anticipated transactions group uses forward contracts foreign currency options optimise certain anticipated foreign exchange revenues cash flows financing transactions notes roche group consolidated financial statementstransaction exposure arises amount local currency paid received trans actions denominated foreign currencies may vary due changes exchange rates many group companies income primarily local currency significant amount expendi ture especially purchase goods resale interest repayment loans foreign currencies similarly transaction exposure arises net balances monetary assets heldin foreign currencies group companies manage exposure local level necessary means financial instruments options forward contracts addition group treasury monitors total worldwide exposure help comprehensive data received monthly basis translation exposure arises consolidation foreign currency denominated finan cial statements groups foreign subsidiaries effect groups consolidated equity shown currency translation movement group hedges significant net investments foreign currencies taking foreign currency loans issuing foreign currency denominated debt instruments major translation exposures monitored regular basis significant part groups cash outflows research development production admin istration denominated swiss francs much smaller proportion groups cash inflows swiss franc denominated result increase value swiss franc rela tive currencies adverse impact consolidated net income similarly relative fall value swiss franc favourable effect results published swiss francs interest rate risk interest rate risk arises movements interest rates could adverse effects thegroups net income financial position changes interest rates cause variations interest income expenses interestbearing assets liabilities addition affect market value certain financial assets liabilities instruments described following section market risk interest rates groups major debt instruments fixed described note reduces groups exposure changes interest rates group companies manage shortterm interest rate risk local level necessary using financial instruments interest rate forward contracts swaps options market risk financial assets changes market value certain financial assets derivative instruments affect net income financial position group financial longterm assets held strategic purposes marketable securities held fund management purposes risk loss value reduced reviews prior investing continuous monitoring performance investments changes risk profile investments equities bonds debentures fixed income instruments entered basis approved guidelines regard liquidity credit rating credit risk credit risk arises possibility counterparty transaction may unable unwilling meet obligations causing financial loss group trade receivables subject policy active risk management focussing assessment country risk credit availability ongoing credit evaluation account monitoring procedures signifi cant concentrations within trade receivables counterparty credit risk due groups large number customers wide geographical spread country risk limits exposures continuously monitored exposure financial assets credit risk controlled set ting policy limiting credit exposure highquality counterparties ongoing reviews credit ratings limiting individual aggregate credit exposure accordingly notes roche group consolidated financial statements liquidity risk group companies need sufficient availability cash meet obligations individual companies responsible cash management including shortterm investment cash surpluses raising loans cover cash deficits subject guidance group certain cases approval group level group maintains sufficient reserves cash readily realisable marketable securities meet liquidity requirements times addition strong international creditworthiness group allows make efficient use international capital markets financing purposes changes group organisation millions chf listing major group subsidiaries associated companies included note changes group organisation following onetime impacts income statement vitamins fine chemicals business impairment net assets disposal vitamins fine chemicals business chugai transaction total disposal vitamins fine chemicals business discussed note invest ment chugai discussed note disetronic effective may group acquired controlling interest disetronic public company headquartered burgdorf switzerland disetronic world leader research development commercialisation insulin pumps injection systems treatment diabetes disetronics infusion systems division become part roche diagnostics diabetes care business area sales disetronics infusion systems division year ended march million swiss francs part acquisition process disetronics injection systems simultaneously resold disetronics founder chairman continues operate independent company group interest disetronic acquisition approved extraordinary general meeting disetronics shareholders april cleared relevant antitrust authorities group paid shareholders disetronic swiss francs cash two roche nonvoting equity securities disetronic share net consideration paid million swiss francs million swiss francs cash million swiss francs form roche nonvoting equity securities addition incidental costs million swiss francs allocation total purchase consideration million swiss francs follows net assets acquired goodwill intangible assets deferred income taxes cash net assets liabilities total goodwill acquired intangible assets amortised straightline basis years years respectively notes roche group consolidated financial statementsfollowing acquisition restructuring programme announced resulted restruc turing charges million swiss francs recorded part operating expenses restructuring programme substantially completed mid igen group acquire controlling interest igen upon closing transaction expected february described note subsequent event isotechnika march july group acquired interest isotech nika inc isotechnika total million swiss francs isotechnika life sciences com pany headquartered canada develops immunosuppressive therapeutic drugs use organ transplant patients treatment autoimmune diseases following acquisition group expected material transactions isotechnika access development milestone payments respect renal transplantation drug isatx materiality transactions group potential exercise significant influence isotechnika accordingly isotechnika reported associated company million swiss francs goodwill arose acquisition together balance acquisition price reported investment associated companies antisoma december group acquired interest antisoma plc antisoma million swiss francs antisoma british biopharmaceutical company develops prod ucts treatment cancer following acquisition group expected material transactions antisoma access development milestone payments respect oncology product portfolio materiality transactions group potential exercise significant influence antisoma accordingly antisoma reported asan associated company million swiss francs goodwill arose acquisition together balance acquisition price reported investment associated companies cash flows changes group organisation shown table amounts net cash balances acquireddivested companybusiness acquisitions subsidiaries associated companies disetronic chugai acquisitions total divestments subsidiaries associated companies vitamins fine chemicals business divestments total notes roche group consolidated financial statements segment information millions chf divisional information roche genentech chugai prescription prescription prescription otc segment revenues segment revenuedivisional sales less interdivisional sales divisional sales third parties operating profit exceptional items amortisation goodwill major legal cases changes group organisation segment resultsoperating profit segment assets liabilities divisional assets segment assets segment assets nonsegment assets total assets divisional liabilities segment liabilities segment liabilities nonsegment liabilities total liabilities segment information capital expenditure depreciation amortisation intangible assets impairment longterm assets restructuring expenses research development costs income associated companies investments associated companies number employees chugai prescription business segment includes results newly merged chugai company includes former nippon roche business october also includes results nippon roche periods september results chugais otc business included otc business segment results chugai prescription business segment include million swiss francs million swiss francs writeoff fair value adjustment inventories arising acquisition accounting chugai see note fair value adjustments written line inventory turnover fully writtenoff end first quarter notes roche group consolidated financial statementstotal core vitamins pharmaceuticals diagnostics others businesses fine chemicals group notes roche group consolidated financial statements geographical information sales third parties destination segment assets capital expenditure switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania segment total nonsegment assets consolidated total sales third parties destination segment assets capital expenditure switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania segment total nonsegment assets consolidated total notes roche group consolidated financial statements genentech effective september group acquired majority interest approximately genentech inc biotechnology company united states june group exer cised option acquire remaining shares genentech june point genentech became owned subsidiary group july october march group completed public offerings genentechs common stock result groups majority interest genentech issues additional shares common stock connection equity compensation plans also may issue additional shares purposes affiliation agreement group genentech provides amongst things genentech establish stock repurchase programme maintain groups percentage ownership interest genentech december groups interest genentech common stock genentech publicly traded listed new york stock exchange symbol dna genentech prepares financial statements conformity accounting principles generally accepted united states us gaap filed quarterly basis us securities exchange commission sec due certain consolidation entries differences requirements international financial reporting standards ifrs us gaap differences genentechs standalone results us gaap basis results genentech consolidated roche group accordance ifrs arereconciled table usd chf usd chf millions millions millions millions operating margin us gaap basis redemption costs special litigation items operating margin nonus gaap basis add deduct differences consolidation entries add back redemption costs differences consolidation entries operating profit exceptional items ifrs basis add deduct exceptional items amortisation goodwill million usd annually major legal cases segment resultoperating profit ifrs basis add deduct nonoperating items ifrs basis financial income income taxes net income ifrs basis minority interest percentage average year income applicable minority interest ifrs basis notes roche group consolidated financial statements differences ifrs us gaap following acquisition group interest genentech june analysis carried acquisition accounting identified amounts attributable inprocess research development iprd genentechs us gaap financial statements items recorded either adjustment equity onetime expense ifrs items classified separate assets date acquisition therefore form part goodwill therefore years subsequent goodwill amortisation expense respect iprd groups results ifrs genentech adopted us accounting standards fas fas effective january goodwill longer amortised subject impairment test least annually ifrs goodwill contin ues amortised also subject testing impairment effective july genentech applied fasb interpretation fin consoli dation variable interest entities us gaap financial statements result genentech consolidated certain leasing structures us gaap financial statements dis closed detail genentechs sec filings reported groups annual financial state ments genentechs leasing structures already consolidated within groups results accordance ifrs property plant equipment concerned capitalised depreciated lease finance reported within longterm debt differences ifrs us gaap relatively minor impact genentech stock repurchases stock options december genentechs board directors authorised stock repurchase programme repurchase million us dollars genentechs common stock december genentech repurchased common stock worth million us dollars million swiss francs earlier genentech repurchased common stock worth million us dollars million swiss francs part earlier stock repurchase programme expired june genentech repurchased million us dollars million swiss francs common stock genentech stock option plan adopted amended plan allows thegranting various stock options stock awards stock appreciation rights employees directors consultants genentech details shown table number options outstanding january granted exercised cancellations outstanding end year exercisable details options granted expiry date average exercise pricein usd proceeds options exercisedin millions usd fair value options granted using blackscholes option valuation model millions us dollars millions swiss francs notes roche group consolidated financial statements options exercised average exercise priceinusd proceeds millions us dollars millions swiss francs terms options outstanding december options outstanding options exercisable weighted average weighted weighted years remaining average average number contractual exercise number exercise range exercise prices usd outstanding life price usd exercisable price usd total net accounting effect genentech stock repurchases stock options recorded minority interests see note matters discussed note group recorded income million swiss francs expense million swiss francs respect certain litigation matters genentech january group issued lyons iv zero coupon us dollar notes exchange able genentech shares notes converted groups percentage owner ship genentech would decrease approximately see also note chugai december roche chugai announced would enter alliance create leading researchdriven japanese pharmaceutical company would formed merger chugai excluding genprobe roches japanese pharmaceuticals subsidiary nippon roche terms alliance chugai nippon roche indepen dently valued roche agreed make additional cash contributions order bring roches par ticipation agreed combined value alliance approved shareholders chugai annual general meeting june newly merged company known chugai fully consolidated subsidiary group roche majority shareholder ownership december minority interest transaction process lateseptember roche acquired public tender offer approximately mil lion shares chugais outstanding shares price jpy per share total cash flow group result tender offer billion japanese yen million swiss francs immediately tender offer roche subscribed issue chugai million new shares price jpy per share resulted cash contribution tochugai billion japanese yen million swiss francs september closing tender offer roche chugai completed spinoff shareholdings ingen probe californiabased diagnostics subsidiary registered shareholders july notes roche group consolidated financial statements october chugai merged nippon roche prior merger nippon roche issued convertible bonds roche group roche cb obligation succeeded chugai october roche acquired additional shares chugai conversion bonds pro portion shares issued chugai conversion convertible bonds previously issued chugai third parties chugai cb roches ownership reached resulted cash contribution billion japanese yen million swiss francs ongoing basis roche convert remaining roche cb chugai shares corresponding conversion remaining chugai cb roche maintains least ownership chugai purchase consideration closing transaction october transaction accounted using purchase method accounting consideration paid roche chugai consists firstly public tender offer secondly subscription new chugai shares con version roche cb relates minority shareholders thirdly net assets nippon roche attributable minority shareholders nippon roche public company net assets nippon roche valued reference fair value chugai shares acquired exchange allocation shown table jpy billions chf millions public tender offer subscription billion jpy convertible bonds billion jpy implied value nippon roche transaction costs purchase consideration chugai acquisition accounting market value chugai shares acquired billion japanese yen million swiss francs corresponds market capitalisation chugai prior transaction purchase consideration billion japanese yen million swiss francs therefore represents surplus billion japanese yen million swiss francs market value chugai shares acquired surplus writtenoff recorded net assets chugai exceed market capitalisation result transaction gain billion japanese yen million swiss francs arises part disposal nippon roche accordingly net income billion japanese yen million swiss francs recognised income statement two amounts acquired net assets chugai shown table amount allocated good includes billion japanese yen million swiss francs attributable inprocess research development international financial reporting standards items classified separate assets date acquisition therefore form part goodwill net assets acquired jpy billions chf millionsa property plant equipment goodwill intangible assets inventories deferred income taxes liabilities postemployment benefits provisions net assets liabilities minority interests total translated september exchange rate jpy chf notes roche group consolidated financial statementsongoing impacts purchase accounting october chugais results included groups consolidated financial state ments chugai prescription shown separate business segment segment informa tion chugai prescription business segment includes results newly merged chugai company includes former nippon roche business october also includes results nippon roche periods september results chugais otc business included otc business segment segment information given note fair value adjustments arising acquisition accounting following impacts groups financial statements th quarter onwards jpy chf jpy chf jpy chf billions millions billions millions billions millionsa writeoff fair value adjustments inventories depreciation property plant equipment amortisation acquired intangible assets amortisation goodwill impact operating profit deferred income taxes impact net income translated december exchange rate jpy chf fair value adjustments inventories fully writtenoff line inventory turnover end first quarter goodwill acquired intangible assets amortised straightline basis years years respectively local statutory financial year june chugais annual general meeting approved change local statutory finan cial yearend march december accordingly chugai ninemonth local fiscal term beginning april thereafter twelvemonth fiscal term beginning january reporting roche group chugai continue report using international finan cial reporting standards drawn date rest roche group dividends dividends distributed thirdparties holding chugai shares totalled mil lion japanese yen million swiss francs october december million japanese yen million swiss francs recorded minority interests see note dividends paid chugai roche eliminated consolidation intercompany items restructuring plan january chugai announced details restructuring plans involving closure sale certain plants facilities japan april chugai announced theadditional closure plan research operations us subsidiary within groups results restructuring costs billion japanese yen million swiss francs recorded restructuring programme substantially completed december share repurchase chugai repurchased common shares total consideration billion japanese yen million swiss francs result groups ownership chugai increased goodwill increased million swiss francs chugai annual general shareholders meeting june authorised repurchase common shares maximum billion japanese yen notes roche group consolidated financial statements stock acquisition rights chugai adopted stock acquisition rights programme programme allows granting rights employees directors chugai right entitles holder purchase chugai shares specified exercise price details shown table number rights outstanding january granted exercised cancellations outstanding end year exercisable details rights granted expiry date june average exercise pricein jpy proceeds rights exercisedin millions jpy fair value rights granted using blackscholes option valuation model millions japanese yen millions swiss francs terms rights outstanding december rights outstanding rights exercisable weighted average years remaining number contractual exercise number exercise year grant outstanding life price jpy exercisable price jpy net accounting effect exercises chugai stock acquisition rights recorded minority interests see note vitamins fine chemicals division millions chf effective september receiving final regulatory approvals group completed sale global vitamins fine chemicals business vfc business dutch company dsm consideration sale million euros million swiss francs con sisted million euros million swiss francs cash million shares dsm market value million euros million swiss francs terms final purchase agreement dsm shares acquired group blocked one two years notes roche group consolidated financial statementsthe sale made cashanddebtfree basis therefore cash received dsm reduced million euros million swiss francs reflect net debt vfc business furthermore terms final purchase agreement dsm certain agreed purchase price adjustment mechanisms mainly related working capital levels vfc business mechanisms resulted purchase price reduction million euros million swiss francs final amounts arising mechanisms including net debt calculation subject review approval group dsm therefore liable change impairment charge million swiss francs recorded december impairment charge million swiss francs recorded june based assessments respective dates difference expected net pro ceeds disposal net assets vfc business taking account residual obligations retained roche group preliminary assessment made december showed additional loss disposal million swiss francs arose onthe disposal vfc business final assessment made following review approval group dsm transaction summarised table eur millions chf millions consideration less net debt adjustment less purchase price adjustment mechanisms net proceeds dsm cash dsm shares incidental transaction costs net assets vfc business net impairment charges accruals residual obligations retained roche group gainloss disposal preliminary assessment disposal results tax benefit currently estimated mil lion swiss francs cash inflow disposal net cash balances million swiss francs held companies within vfc business million swiss francs following sale vfc business certain assets liabilities vitamins fine chemicals division mainly associated vitamin case remain group described section vitamin case addition group given dsm certain indemnities respect remedial actions sites vfc business may required environmental laws arrangements put place regarding utilisation certain assets certain purchasing contracts well adopting dsm preferred supplier pharmaceutical ingredients one arrangements group guaranteed purchase period four years beginning january products sales value totalling million euros group reimburse dsm unutilised amounts arrangements consist certain residual obligations fully accrued notes roche group consolidated financial statements vitamins fine chemicals division shown discontinuing operation con solidated results amounts included groups consolidated income statement thevitamins fine chemicals division shown table results thevfc business included consolidated results group sale september vitamin case vitamins vfc business residual amounts fine chemicals division income statement sales third parties expenses operating profit exceptional items amortisation goodwill major legal cases changes group organisation operating profit result associated companies financial income profit taxes income taxes profit taxes minority interests net income amounts groups consolidated balance sheet vfc business shown table december december balance sheet property plant equipment longterm assets current assets total assets longterm debt noncurrent liabilities current liabilities total liabilities net assets amounts included groups consolidated cash flow statement vfc business shown table cash flows results vfc business included consolidated results group sale september statement cash flows operating activities financing activities investing activities net effect currency translation cash increase decrease cash notes roche group consolidated financial statementsvitamin case following settlement agreement us department justice may regarding pricing practices vitamin market overall settlement agreement class action suitbrought us buyers bulk vitamins group recorded provisions respect vitamin case provisions groups best estimate time total liability may arise taking account currency movements time value money provisions legal fees recorded separately december december based development litigation recent settlement negotiations group recorded additional provisions million swiss francs respectively january district columbia circuit court appeals ruled nonus plaintiffs may bring claims us courts us antitrust laws alleged damages suffered trans actions outside united states connection vitamin case defendants including roche filed petition asking supreme court review case december supreme court decided consider appeal defendants provisions recorded respect litigation eventual outcome uncertain stage total payments year million swiss francs million swiss francs charged provisions previously recorded payments made include million us dollars million swiss francs direct customers united states group seeking resolve remaining outstanding issues however timing final amounts involved uncertain remaining provisions recorded total million swiss francs based current litigation recent settlement agreements provisions areall considered shortterm cash outflows expected arise discounted time value money considered material case litigation negotiations progress possible ultimate liability may different amount provisions currently recorded part disposal process liabilities respect vitamin case remain roche group roche dsm signed indemnity cooperation agreement roche may provide dsm certain indemnities guarantees connection vitamin case major legal cases millions chf igen litigation writeoff intangible assets release provisions genentech legal cases payments settlements additional provisions total notes roche group consolidated financial statements igen litigation february united states district court maryland entered judgement civil litigation roche diagnostics gmbh germany rdg igen international inc igen claims related licensing igens electrochemiluminescence ecl technology rdg court concluded several breaches licence agreement material igen right terminate licence agreement awarded igen million us dollars compensatory damages million us dollars punitive damages july united states court appeals fourth circuit reversed substantial damages awarded rdg court reversed finding rdg engaged unfair competition continuation patent lawsuit igen one rdgs affiliated companies setting aside claim court eliminated basis award million us dollars punitive damages rdg court also held rdg violate implied covenant good faith fair dealing license agreement thereby also setting aside award million us dollars compensatory damages claim total court eliminated million usdollars million us dollars judgement entered rdg court left intact thejurys award remaining damages finding igen may terminate license agreement rdg igen notified rdg igen terminate license agreement july group igen announced plans thegroup acquire igen thisacquisition expected completed february see note previous license agreement terminated group writtenoff intangible assets technology recorded time acquisition corange group roche group net book value million swiss francs time group released income million swiss francs litigation provisions balance provision less remaining outstanding compensatory damages awards net two amounts expense totalling million swiss francs recorded expense major legal cases march rdg paid million us dollars collateral deposit account relation theigen litigation following entry final judgement rdg paid remaining million usdollars million swiss francs respect remaining compensatory damages igen amount collateral deposit account repaid group net cash inflow two transactions million swiss francs genentech legal cases group recorded income million swiss francs respect certain litigation settlements including litigation involving amgen group recorded provision million swiss francs respect certain litigation matters including litigation involving thecity hope june genentech announced los angeles county superior court jury voted toaward city hope medical center approximately million us dollars compensatory damages based finding breach agreement genentech city ofhope june jury voted award city hope million us dollars punitive damages case september genentech filed notice appeal jury verdict damages awards california court appeal appeals process ongoing take one four years depending scope review full provision notes roche group consolidated financial statementsbeen recorded awards appeals process interest accrues total amount damages simple annual rate following judgement interest million usdollars million swiss francs million us dollars million swiss francs recorded asthe time cost provisions within interest expenses see note october genentech entered arrangement third party insurance companies post surety bond million us dollars connection judgement part arrange ment genentech pledged million us dollars cash investments secure bond amounts equivalent million swiss francs reported restricted cash within financial longterm assets see note addition genentech party patent infringement suit filed chiron corporation june us district court eastern district california sacramento respect herceptin june court issued several decisions regarding summary judgement motions filed jury trial suit began august following first phase trial based findings jury court entered judgement favour genentech november chiron filed notice appeal us court appeals federal circuit december genentech filed notice crossappeal court appeal process ongoing august united states patent trademark office declared interference chiron patent involved lawsuit patent application exclusively licensed genentech university pennsylvania relating antiher antibodies declaring interference patent office determined substantial question whether inventors chiron patent first invent technology involved entitled patent connection second patent infringement lawsuit filed march genentech chiron discovery case currently stayed january arbitration proceedings began genentech tanox biosystems inc tanox regarding july settlement crosslicensing agreement relating development manufacture certain antibody products directed towards immunoglobin e including xolair hu tanox claimed breaches agreement genentech made counterclaims genentech continues work arbitration process tanox parties agreed postpone decision arbitration earliest decision made late february provisions recorded respect arbitra tion outcome determined date financial statements august genentech amgen inc announced settlement patent litigation us district court northern district california settlement agreement parties agreed dismiss claims counterclaims part settlement amgen made onetime payment genentech november genentech bayer settled breach contract action genentech brought bayer relating bayers manufacture sale factor viii license agreement bayer genentech part settlement bayer made onetime payment genentech income major legal cases million swiss francs recorded respect settlements genentech party litigation described genentechs annual report quarterly sec filings however matters far advanced matters referred notes roche group consolidated financial statements employee benefits millions chf wages salaries social security costs postemployment benefits defined benefit plans postemployment benefits defined contribution plans employee benefits total employees remuneration charges employee benefits included relevant expenditure line function thenumber employees yearend employee benefits consist mainly life insurance schemes certain insurance schemes providing medical dental cover pensions postemployment benefits millions chf employees covered retirement benefit plans sponsored group companies nature plans varies according legal regulations fiscal requirements economic con ditions countries employees employed majority plans defined benefit plans largest located switzerland united states germany united kingdom japan postemployment benefits consist mostly postretire ment healthcare life insurance schemes principally united states plans usually funded payments group employees trusts independent groups finances plan unfunded notably major defined benefit plans germany liability whole obligation recorded groups balance sheet amounts recognised arriving operating profit postemployment defined benefit plans follows current service cost interest cost expected return plan assets net actuarial gains losses recognised past service cost gains losses curtailment total included employees remuneration actual return plan assets million swiss francs negative return million swiss francs september group paid additional contribution million us dollars mil lion swiss francs postemployment defined benefit plan one us subsidiaries due falls market value plans assets payment included contri butions paid table accounted part recognised surplus funded pension plans see also note groups consolidated financial statements thereafter included actuarial calculation groups pension expenses andbalances notes roche group consolidated financial statementsthe movements net asset liability recognised balance sheet postemployment defined benefit plans follows beginning year disetronic chugai vitamins fine chemicals business total expenses included employees remuneration contributions paid benefits paid unfunded plans currency translation effects end year amounts recognised balance sheet postemployment defined benefit plans follows funded plans actuarial present value funded obligations due past present employees plan assets held trusts fair value plan assets excess deficit actuarial present value funded obligations unrecognised actuarial gains losses unrecognised past service costs net recognised asset liability funded obligations due past present employees unfunded plans recognised liability actuarial present value unfunded obligations due past present employees total recognised asset liability funded unfunded obligations due past present employees reported surplus recognised part longterm assets deficit recognised part liabilities postemployment benefits total net asset liability recognised amounts include nonpension postemployment benefit schemes principally medical plans follows actuarial present value obligations due past present employees plan assets held trusts fair value plan assets excess deficit actuarial present value funded obligations less unrecognised actuarial gains losses net recognised asset liability amounts recognised balance sheet postemployment defined benefit plans pre dominantly noncurrent reported longterm assets noncurrent liabilities plan assets funded plans include groups equity instruments nonvoting equity securities fair value million swiss francs notes roche group consolidated financial statements group operates defined benefit schemes many countries actuarial assumptions vary based upon local economic social conditions range assumptions used actuarial valuations significant defined benefit plans countries stable currencies interest rates follows weighted weighted average range average range discount rates projected rates remuneration growth expected rates return plan assets healthcare cost trend rate employee stock options equity compensation benefits millions chf roche option plan group offers nonvoting equity security options certain directors management exercise price market price nonvoting equity securities date issue options nontradable sevenyear duration vest phased basis three years group covers obligations purchasing nonvoting equity securities derivatives thereon see note cost instruments reported equity instru ments within equity balance sheet options exercised cash received credited equity instruments impacts income statement employer social insurance costs administrative costs plan previous option compensation plan whereby group purchased options directly third party financial insti tutions granted certain employees closed existing option grants old plan continue options granted details roche option plan shown table number options outstanding january granted exercised cancellations outstanding end year exercisable details options granted expiry date february february july andaugust average exercise price chf proceeds options exercisedin millions chf fair value options granted using blackscholes option valuation modelin millions chf options exercised average exercise price chf proceeds millions chf notes roche group consolidated financial statementsterms options outstanding december options outstanding options exercisable weighted average weighted weighted years remaining average average number contractual exercise number exercise year grant outstanding life price chf exercisable price chf total roche performance share plan group offers future nonvoting equity security awards boards discretion cash equivalent certain directors key senior management programme established beginning effect three years amount nonvoting equity securities granted depends upon individuals salary level achievement performance targets linked groups total shareholders return shares nonvoting equity securities combined relative groups peers threeyear period date grant grants vest three years final number nonvoting equity securities awarded equivalent original grant depending final total share holders return performance approved board directors close financial year settled number original grants outstanding december cost plan accrued vesting period grant based final cash outflow estimated balance sheet date year cost ofthe plan million swiss francs million swiss francs reported within relevant operating expense categories roche connect programme enables employees worldwide except united states cer tain countries make regular deductions salaries purchase nonvoting equity securities administered independent third parties group makes contribution programme allows employees purchase nonvoting equity securities discount usually administrator purchases necessary nonvoting equity securities directly market nonvoting equity securities held december programme operational since october year cost plan million swiss francs million swiss francs reported within relevant operating expense categories stock appreciation rights employees certain us subsidiaries group receive stock appreciation rights sars part compensation sars may exercised vesting period one three years cash payment based upon amount market price ofthe groups american depositary receipts adrs point exercise exceeds strike price grant price issuance number rights outstanding january granted exercised cancellations outstanding end year exercisable notes roche group consolidated financial statements details rights granted expiry date february december average exercise price usd fair value right granted using blackscholes option valuation model millions us dollars millions swiss francs rights exercised average exercise price usd cash outflow millions us dollars millions swiss francs amounts recorded consolidated financial statements expense millions chf accrual millions chf terms rights outstanding december rights outstanding rights exercisable weighted weighted average average number exercise number exercise year grant outstanding expiry price usd exercisable price usd prior awards award award award total genentech chugai plans genentech stock option plan discussed note chugai stock acquisition rights programme discussed note operating income millions chf royalty income gains disposal products total operating income part ongoing alignment product portfolio group periodically disposes product lines longer considered core products september group announced sale protein design labs pdl business related zenapax product worldwide disease indications organ transplantation group continue market zenapax transplantation indications point pdl option purchase cash received million swiss francs october group completed sale amgen business related neupogen products european union switzerland norway thecash received million swiss francs disposals products concerned book value gain disposal cash proceeds disposals reported within operating profit roche prescription segment notes roche group consolidated financial statements operating expenses millions chf royalty expenses restructuring expenses impairment longterm assets total operating expenses operating expenses include million swiss francs restructuring expenses million swiss francs impairment longterm assets pharmaceuticals division restructuring programme reported within operating profit roche prescrip tion segment previously separately disclosed income statement financial income millions chf gains sale equity securities losses sale equity securities gains labcorp transactions dividend income gains losses equity derivatives net writedowns impairments equity securities net income equity securities interest income gains sale debt securities losses sale debt securities writedowns impairments longterm loans net interest income income debt securities interest expense amortisation discount debt instruments gains losses interest rate derivatives net time cost provisions net interest expense foreign exchange gains losses net gains losses foreign currency derivatives net net foreign exchange gains losses net financial income expense total net financial income gains labcorp transactions march july group sold remaining shares labcorp transactions resulted pretax gain incidental costs million swiss francs amounts recorded part financial income net pretax cash inflow million swiss francs addition group realised gain million swiss francs equity derivatives entered connection disposal labcorp shares group remaining ownership interest labcorp outstanding derivative positions labcorp equities notes roche group consolidated financial statements impairment financial assets december group revised accounting estimates impairment financial assets addition existing impairment triggers described note available forsale financial assets market value original cost net previous impairment sustained six month period considered impaired falls market price less original cost net previous impairment less sustained sixmonth period considered objective evidence ofimpairment movements fair value recorded equity objective evidence impairment asset sold otherwise disposed result revision accounting estimate group recorded exceptional impairment charge million swiss francs effective december writedowns impairments equity securities million swiss francs mostly arise availableforsale financial assets market value original cost sustained sixmonth period considered impaired mainly relate equity securities december market value limit less sustained sixmonth period income taxes millions chf income tax expenses amounts charged income statement follows current income taxes deferred income taxes total charge income taxes since group operates across world subject income taxes many different tax jurisdictions group calculates average expected tax rate weighted average tax rates tax jurisdictions group operates rate increased operating income became considerably higher proportion pretax income case previous years caused increase groups effective tax rate operating income typically occurs jurisdictions higher tax rates compared financial income groups average expected tax rate stabilised within groups average expected tax rate increasing significance genentech chugai causes increase rate offset ongoing improvement groups structures groups effective tax rate reconciled groups average expected tax rate follows groups average expected tax rate tax effect unrecognised tax losses gain sale labcorp shares nontaxable incomenondeductible expenses impairment financial assets differences continuing businesses exceptional items effective tax rate notes roche group consolidated financial statements impact impact impact impact profit tax income taxes tax rate profit tax income taxes tax rate continuing businesses exceptional items effective tax rate amortisation goodwill major legal cases changes group organisation exceptional impairment financial assets continuing businesses effective tax rate discontinuing businesses groups effective tax rate income tax assets liabilities amounts recognised balance sheet income taxes follows current income taxes current income tax assets current income tax liabilities net current income tax asset liability balance sheet deferred income taxes deferred income tax assets deferred income tax liabilities net deferred income tax asset liability balance sheet decrease current income tax assets due reimbursement swiss withholding taxes tax receivable united states deferred income tax assets recognised tax loss carry forwards extent realisation related tax benefit probable group unrecognised tax losses including valuation allowances million swiss francs million swiss francs million swiss francs expires within five years remaining million swiss francs losses expire fifteen years expiry limit deferred income tax liabilities established withholding tax taxes would payable unremitted earnings certain foreign subsidiaries amounts currently regarded permanently reinvested unremitted earnings totalled billion swiss francs december billion swiss francs deferred income tax assets liabilities deferred income tax charges credits attributable following items property plant equipment restructuring temporary intangible assets provisions differences total net deferred income tax asset liability beginning year charged credited income statement charged credited equity disetronic disposal vitamins fine chemicals business currency translation effects net deferred income tax asset liability end year notes roche group consolidated financial statements property plant equipment restructuring temporary intangible assets provisions differences total net deferred income tax asset liability beginning year charged credited income statement charged credited equity chugai currency translation effects net deferred income tax asset liability end year property plant equipment millions chf buildings land machinery improve construction land ments equipment progress total total net book value beginning year disetronic chugai disposal vitamins fine chemicals business additions disposals transfers depreciation charge impairment charges currency translation effects end year december cost accumulated depreciation net book value finance leases december capitalised cost machinery equipment finance leases amounts million swiss francs million swiss francs net book value assets amounts million swiss francs million swiss francs operating leases future minimum annual payments noncancellable operating leases follows within one year one five years thereafter total minimum annual payments total operating lease rental expense million swiss francs million swiss francs group capital commitments purchase construction property plant equipment totalling billion swiss francs billion swiss francs notes roche group consolidated financial statements goodwill millions chf net book value beginning year disetronic chugai amortisation charge impairment charge vitamins fine chemicals impairment net assets currency translation effects end year december cost accumulated amortisation net book value genentech acquisition corange acquisition chugai acquisition disetronic acquisition others total goodwill arising investments associated companies classified part theinvestments associated companies see note goodwill million swiss francs arising investment antisoma december reclassified goodwill previously published balance sheet intangible assets millions chf patents licences acquisition trademarks related total total net book value beginning year disetronic chugai additions disposals amortisation charge impairment charge vitamins fine chemicals impairment net assets igen litigation currency translation effects end year notes roche group consolidated financial statements patents licences acquisition trademarks related total total december cost accumulated amortisation net book value genentech acquisition corange acquisition chugai acquisition disetronic acquisition kytril others total kytril intangible assets arise purchase group global rights kytril granisetron smithkline beecham december million swiss francs group currently internally generated intangible assets development criteria forthe recognition asset met associated companies millions chf group investments associated companies listed accounted using equity method share net income balance sheet value basilea pharmaceutica switzerland investments associated companies total investments associated companies goodwill arising investments associated companies classified part investments associated companies goodwill million swiss francs arising investment antisoma december reclassified goodwill previ ously published balance sheet see note basilea pharmaceutica group owns noncontrolling interest inbasilea pharmaceutica ltd basilea basilea swiss biotechnology company anti bacterial antifungal dermatology fields groups major investments associates tripath inc isotechnika antisoma additional information companies given note transactions group associated companies given note notes roche group consolidated financial statements joint ventures millions chf groups interests joint ventures reported financial statements using propor tionate consolidation method significant joint ventures detailed bayer joint venture group stake bayer roche llc joint venture bayer group overthecounter otc field market distribute product aleve certain otc products united states effect groups joint ventures income statement balance sheet follows income statement sales expenses net income taxes balance sheet longterm assets current assets noncurrent liabilities current liabilities net assets financial longterm assets millions chf availableforsale investments heldtomaturity investments loans receivable longterm trade receivables restricted cash total financial longterm assets financial longterm assets held strategic purposes therefore classified non current effective interest rate heldtomaturity investments loans receivable comprise loans third parties term one year restricted cash consists million us dollars million swiss francs cash invest ments pledged genentech connection city hope litigation see note cashset aside collateral certain lease agreements restricted cash also included million us dollars paid collateral deposit account respect igen litigation seenote million swiss francs pledged roche group companies collateral connection obligation repurchase equity instruments see note notes roche group consolidated financial statements longterm assets millions chf recognised surplus funded pension plans prepaid employee benefits total longterm assets longterm assets consist various assets otherwise shown separately group expects derive economic benefits one year inventories millions chf raw materials supplies work process finished goods less provision slowmoving obsolete inventory total inventories inventories held net realisable value carrying value million swiss francs million swiss francs result disposal vitamins fine chemicals business inventories decreased million swiss francs effective september see note accounts receivable millions chf trade accounts receivable notes receivable less provision doubtful accounts total accounts receivable december accounts receivable include amounts denominated us dollars equivalent billion swiss francs billion swiss francs amounts denominated euros equivalent billion swiss francs billion swiss francs bad debt expense million swiss francs million swiss francs current assets millions chf accrued interest income prepaid expenses derivative financial instruments receivables total current assets marketable securities millions chf heldfortrading investments bonds debentures availableforsale current investments shares bonds debentures money market instruments time accounts three months total marketable securities notes roche group consolidated financial statementsmarketable securities held fund management purposes therefore classified current investments held strategic purposes classified noncurrent see note shares consist primarily readily saleable equity securities bonds debentures average effective contracted maturity amount interest rate within one year one five years five years total bonds debentures within one year one five years five years total bonds debentures money market instruments generally fixed interest rates ranging depending upon currency denominated theyare contracted mature within one year december accounts payable millions chf trade accounts payable taxes payable accounts payable total accounts payable accrued current liabilities millions chf deferred income accrued payroll related items interest payable derivative financial instruments accrued liabilities total accrued current liabilities notes roche group consolidated financial statements provisions contingent liabilities millions chf environmental legal restructuring provisions provisions provisions total total beginning year chugai changes group organisation vitamin case additional provisions created utilised year major legal cases additional provisions created unused amounts reversed utilised year provisions additional provisions created unused amounts reversed utilised year increase discounted amount due passage time change discount rate currency translation effects end year current portion provisions noncurrent portions provisions total provisions expected outflow resources within one year one two years two three years three years total provisions environmental legal provisions provisions include million swiss francs million swiss francs environmen tal matters million swiss francs million swiss francs litigation includ ing major legal cases vitamin case provisions environmental matters cover various separate environmental issues number ofcountries approximately half preexisting companies acquired group group recorded additional environmental provisions respect certain indemnities given dsm respect remedial actions sites vfc business see note bytheir nature amounts timing outflows difficult predict group estimates approximately half amount provided may result cash outflows thenext five years significant provisions discounted notes roche group consolidated financial statementslegal provisions consist mainly major legal cases notably city hope medical center litigation see note vitamin case see note amounts timing uncertainties outflows discussed notes discount rates used remaining legal provisions account less balance consist number separate legal matters various group companies majority cash outflows expected occur within next one three years although dependent development thevarious litigations significant provisions discounted major legal cases described note vitamin case described note litigation matters currently significant described carvedilol arbitration roche diagnostics gmbh rdg smithkline beecham cork ltd sb party arbitration concerning rdgs termination carvedilol license agreement amended relating licensing comarketing carvedilol rdg submitted claim damages arbitration tribunal zurich sb sub mitted counterclaim asserting invalidity rdgs termination claiming damages final decision arbitration tribunal expected earliest amount pro visions recorded rdg disclosed may seriously prejudice rdgs position inthis matter applera litigation october applera corporation applera filed suit group superior court california filed notice arbitration american arbi tration association superior court lawsuit arbitration demand make claims con cerning interpretation enforcement contracts group applera commercialisation polymerase chain reaction pcr technology claims seek termina tion certain contracts declarations regarding rights obligations contracts monetary damages relief unspecified amount alleged breaches various agreements parties december group filed response arbi tration proceeding group generally denied claims made counterclaims applera declarations concerning respective rights obligations parties contracts including alleged breach appleras obligation source certain enzymes group damages december group also responded appleras complaint superior court proceeding petitioning court compel arbitration claims alleged applera stay lawsuit pending completion arbitration court yet ruled groups petition hearing trial date yet set either arbitration proceeding superior court lawsuit provisions recorded respect matters outcome determined date financial statements promega litigation group filed suit promega corporation promega alleging patent infringement breach licence agreement relating polymerase chain reaction pcr technology litigation currently us district court northern district california decision enforceability one patents concerned expected november group notified promega filed non public qui tam action group us district court eastern district west virginia march complaint filed false claims act alleges us federal government overcharged purchase pcr enzyme products july us federal government notified court decision intervene promegas complaint november court ordered complaint unsealed group intends file motion dismiss complaint provisions recorded respect litigation notes roche group consolidated financial statements restructuring provisions arise planned programmes materially change scope business undertaken group manner business conducted provisions include costs necessarily entailed restructuring associated ongoing activi ties group expected outflows include remaining million swiss francs relat ing restructuring disetronic million swiss francs relating closure costs part pharmaceuticals division restructuring announced remaining amounts mostly respect obligations towards former employees arising pharma ceuticals division restructuring previous restructuring plans timings cash outflows reasonably certain global basis shown table significant provisions discounted provisions provisions consist mostly claims arising trade various provisions group companies fit categories timings cash outflows bytheir nature uncertain best estimates shown table provisions discounted time value money considered material case contingent liabilities operations earnings group continue time time varying degrees tobe affected political legislative fiscal regulatory developments including relating environmental protection countries operates industries group engaged also subject physical risks various kinds nature frequency ofthese developments events covered insurance well effect future operations earnings predictable see also note respect vitamin case note respect major legal cases group entered strategic alliances various companies order gain access topotential new products utilise companies help develop groups potential new products potential future payments may become due certain collaboration partners achieving certain milestones defined collaboration agreements groups best esti mate future commitments payments million swiss francs million swiss francs million swiss francs noncurrent liabilities millions chf deferred income longterm liabilities total noncurrent liabilities notes roche group consolidated financial statements debt millions chf debt instruments amounts due banks financial institutions capitalised lease obligations obligation repurchase equity instruments borrowings total debt reported longterm debt shortterm debt total debt repayment terms debt within one year one two years two three years three four years four five years thereafter total debt lyons zero coupon us dollar exchangeable notes see reflected due first year holders notes request group purchase notes fair value debt instruments billion swiss francs billion swiss francs fair value total debt billion swiss francs billion swiss francs iscalculated based upon present value future cash flows instrument discounted market rate interest instruments similar credit status cash flows maturity periods pledges groups assets connection debt except noted theobligation arising leases genentech supported restricted cash million usdollars million swiss francs addition obligation secured property plant equipment net book value million swiss francs december amounts due banks financial institutions interest rates amounts primarily denominated us dollars euros average approximately repayment dates vary years million swiss francs million swiss francs due within one year notes roche group consolidated financial statements debt instruments carrying value groups debt instruments given table effective interest rate european medium term note programme bonds due october principal million euros bonds due august principal million pounds sterling bonds due october principal million us dollars swiss franc bonds bullet due march principal billion swiss francs rodeo due march principal billion swiss francs us dollar bonds chameleon due july principal billion us dollars swiss franc convertible bonds helveticus dividendlinked convertible bonds due july principal billion swiss francs zero coupon us dollar exchangeable notes lyons ii due april principal billion us dollars lyons iii due may principal billion us dollars lyons iv due january principal billion us dollars lyons v due july principal billion us dollars japanese yen exchangeable bonds sumo due march principal billion japanese yen limited conversion preferred stock due november japanese yen convertible bonds issued chugai series chugai pharmaceutical unsecured convertible bonds due september principal amount billion japanese yen total debt instruments issues new debt instruments net proceeds shown table european medium term note programme eurodenominated bonds issued april sterlingdenominated bonds issued august us dollardenominated bonds issued october total issues year notes roche group consolidated financial statementsrepayments redemptions conversions debt instruments net cash outflows shown table bullet swiss franc bonds repayment principal due date march lyons ii us dollar exchangeable notes exercise group option redeem principal plus accrued original issue discount oid april helveticus swiss franc convertible bonds additional cash payment chf per bond upon conversion remaining principal due date july samurai japanese yen bonds repayment principal due date may total repayments retirements year conversion helveticus swiss franc convertible bonds due date july remaining swiss franc convertible bonds originally issued converted nonvoting equity securities genussscheinea total nonvoting equity securities used meet conversion obligations helveticus bonds accordance terms bonds additional cash payment chf per bond made upon conversion remaining principal conversion reduced debt million swiss francs million swiss francs form nonvoting equity securities million swiss francs form cash terms outstanding convertible debt instruments lyons iii notes exchangeable american depositary shares adss exchange ratio exchange adss per usd principal amount maturity notes group purchase note cash option holder may may purchase price per usd principal amount notes usd usd respectively addition notes redeemable option group whole part time may issue price plus accrued original issue discount oid ifthe notes outstanding december exchanged would require nonvoting equity securities meet obligation lyons iv notes exchangeable genentech shares exchange ratio genentech shares per usd principal amount time maturity notes group right pay cash equal market value genentech shares lieu delivering genentech shares group purchase note cash option holder january january purchase price per usd principal amount notes usd usd respectively addition notes redeemable option group whole part time january issue price plus accrued original issue discount oid notes outstanding december exchanged would require genentech shares meet obligation notes converted groups percentage ownership genentech would decrease approximately lyons v notes exchangeable adss exchange ratio exchange adss per usd principal amount maturity notes group purchase note cash option holder january july july purchase price per usd principal amount notes usd usd usd respectively addition notes redeemable option group whole part time july issue price plus accrued original issue discount oid notes outstanding december exchanged would require nonvoting equity securities meet obligation notes roche group consolidated financial statements sumo bond jpy par value exchangeable nonvoting equity securities roche holding ltd bonds redeemable maturity issue price plus accrued original issue discount oid bonds outstanding december exchanged would require nonvoting equity securities tomeet obligation limited conversion preferred stock limited conversion preferred stock substance afinancial liability rather equity instrument therefore classified longterm debt balance sheet related dividend payments treated interest expense thepar value share usd shares subject mandatory redemption november par plus accrued annual interest share exchangeable option holder nonvoting equity securities redeemable option holder par plus accrued annual interest november year shares outstand ing december converted would require nonvoting equity securities meet obligation series chugai pharmaceutical unsecured convertible bonds bond jpy par value convertible shares chugai conversion option bondholder may made time due date september bonds redeemable maturity issue price bonds outstanding december converted would require chugai shares exactly meet obligation groups percentage ownership chugai would affected conversion group bonds convertible chugai shares mirror chugai outstanding third parties see also note unamortised discount included within carrying value debt instruments following unamortised discounts swiss franc bonds us dollar bonds euro bonds sterling bonds zero coupon us dollar exchangeable notes japanese yen exchangeable bonds total unamortised discount derivative financial instruments millions chf appropriate circumstances group uses derivative financial instruments part risk management trading strategies discussed note derivative financial instruments carried fair value methods used determining fair value described note foreign currency derivatives forward exchange contracts swaps options interest rate derivatives swaps derivatives total carrying value derivative financial instruments notes roche group consolidated financial statements assets liabilities recognised current assets accrued current liabilities total net asset liability recognised hedge accounting groups accounting policy hedge accounting described note requires qualify hedge accounting hedging relationship must meet several strict conditions ondocumentation probability occurrence hedge effectiveness reliability measurement described note group financial risk management policies cover foreign exchange risk interest rate risk market risk credit risk liquidity risk deemed appropri ate certain risks altered use derivatives many transactions considered hedges economic terms required conditions met relationship qualify hedge accounting case hedging instru ment hedged item reported independently hedging relationship means derivatives reported fair value changes fair value included financial income group generally limits use hedge accounting certain significant transactions conse quently december group fair value hedges cash flow hedges hedges net investment foreign entity meet strict requirements qualify hedge accounting apart described igen acquisition groups sub sidiary genentech connection proposed acquisition igen group would contribute million us dollars igen purchase igens shares million us dollars giving total cash outflow million us dollars group contributed million us dollars equity acquisition vehicle remaining million us dollars funded liquid funds held swiss francs euros group entered forward contracts buy million us dollars swiss francs million us dollars euros order hedge foreign exchange risk could arise movements us dollar exchange rate ward rates chfusd eurusd value dateis february fair values forward contracts december nega tive million swiss francs negative million swiss francs respectively genentech nonus dollar cash flows future royalty income development expenses expected next one five years hedge part transaction exposure genentech enters derivative financial instruments options forward contracts instruments outstanding december genentech equity investments various biotechnology companies subject greater risk market fluctuation stock market general manage part exposure genentech enters derivative finan cial instruments zero cost collars forward contracts december instruments designated qualify cash flow hedges recorded balance sheet fair value million swiss francs matters also described genen techs annual report quarterly sec filings movements fair value reserve designated cash flow hedges included note notes roche group consolidated financial statements equity share capital december share capital roche holding ltd groups parent company consists shares preceding year shares bearer shares group maintain register shareholders based information supplied tothegroup shareholders group pooled voting rights owns ofthe issued shares described note based information supplied thegroup novartis international ltd basel affiliates owns participation issued shares nonvoting equity securities genussscheine december nonvoting equity securities issue preced ing year swiss company law nonvoting equity securities nominal value part share capital issued contribution would shown asset balance sheet roche holding ltd nonvoting equity security confers rights shares participate net profit remaining proceeds liquidation following repayment nominal value shares participation certificates accordance law articles incorporation roche holding ltd company entitled times exchange nonvoting equity securities shares participation certificates dividends april shareholders approved distribution dividend swiss francs per share nonvoting equity security swiss francs respect business year distribution holders outstanding shares nonvoting equity securities totalled million swiss francs million swiss francs recorded retained earnings board proposed dividends business year swiss francs per share nonvoting equity security subject approval annual general meeting april equity instruments following redemption lyons ii exchangeable notes april see note light ongoing restructuring groups treasury operations debt financing group carried comprehensive review arrangements whereby covers potential conversion obligations may arise convertible debt instruments group refinanced various instruments cover potential obligations deliver nonvoting equity securities group sold nonvoting equity securities pre viously held series transactions addition nonvoting equity securities utilised disetronic transaction see note utilised conversion helveticus bonds see note group also agreed counterparties restructure previous arrangements used writtenshort put options purchasedlong call options strike price combined effect forward purchase december arrangements closed addition group pur chased various counterparties low exercise price options lepos give group right purchase nonvoting equity securities low strike price notes roche group consolidated financial statementsconsequently group following holdings equity instruments equivalent num ber nonvoting equity securities december december nonvoting equity securities low exercise price options forward purchases derivative instruments total nonvoting equity instruments equity instruments recorded within equity original cost acquisition details equity instruments held december shown table fair values dis closed information purposes equivalent number fair value nonvoting strike price millions equity securities maturity chf chf nonvoting equity securities na na low exercise price options feb apr derivative instruments roche option plan feb feb options feb apr total nonvoting equity securities low exercise price options held potential conversion obligations may arise groups convertible debt instruments see note groups potential obligations employees roche option plan see note covered call options exercisable time maturity group also holds resid ual number options purchased use groups previous option compensation scheme closed see note december amounts recorded debt forward contracts purchase nonvoting equity securities december million swiss francs amounts recorded financial longterm assets collateral cover forward purchases december million swiss francs net cash outflow transactions equity instruments regarding refinancing instruments covering convertible debt obligations million swiss francs net cash outflow transactions equity instruments mil lion swiss francs netcash inflow million swiss francs group holds none shares notes roche group consolidated financial statements earnings per share nonvoting equity security basic earnings per share nonvoting equity security continuing businesses group net income millions chf number shares millions number nonvoting equity securities millions weighted average number nonvoting equity securities held millions weighted average number shares nonvoting equity securities issue used calculate basic earnings per share millions basic earnings per share nonvoting equity security chf diluted earnings per share nonvoting equity security calculation diluted earnings per share nonvoting equity security net income weighted average number shares nonvoting equity securities outstanding adjusted effects dilutive potential shares nonvoting equity securities potential dilutive effects arise convertible debt instruments employee stock option plans outstanding convertible debt instruments converted would lead reduction interest expense increase number shares may havea net dilutive effect earnings per share exercise outstanding vested employee stock options would dilutive effect exercise outstanding vested genentech employee stock options would dilutive effect net income genentech positive diluted earnings per share nonvoting equity security shows potential impacts ofthese dilutive effects earnings per share figures continuing businesses group net income millions chf elimination interest expense net tax convertible debt instruments dilutive millions chf increase minority share group net income net tax assuming outstanding genentech stock options exercised millions chf net income used calculate diluted earnings per share millions chf weighted average number shares nonvoting equity securities issue millions adjustment assumed conversion convertible debt instruments dilutive millions weighted average number shares nonvoting equity securities issue used calculate dilutive earnings per share millions diluted earnings per share nonvoting equity security chf notes roche group consolidated financial statements fair value reserves millions chf fair value fair value reserve reserve available qualifying equity currency forsale cash flow conversion translation investments hedges options reserve total total beginning year changes fair value recognised net income deferred income taxes minority interests currency translation gains losses end year minority interests millions chf beginning year chugai acquisition part disposal nippon roche disposal vitamins fine chemicals minority share group net income net tax net effect movements fair value charged credited equity net effect exercise genentech stock options genentech stock repurchases chugai stock repurchases chugai dividend payments currency translation effects end year genentech chugai total minority interests related parties millions chf controlling shareholders share capital roche holding ltd groups parent company consists bearer shares based information supplied shareholders group pooled voting rights comprising dr lukas hoffmann ms vera michalskihoffmann ms maja hoffmann mrandr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri ms beatrice oeri ms maja oeri mr fritz gerber group holds shares preceding year represents issued shares figure include shares without pooled voting rights held outside group individual members group mr andr hoffmann dr andreas oeri mr fritz gerber members board directors roche holding ltd capacity receive annual remuneration thousand swiss francs addition mr hoffmann dr oeri receive thousand swiss francs thousand swiss francs respectively time expenses related membership board com mittees mr gerber receive benefits roche pension funds receipt annual pension group since may pension thousand swiss francs supplementary information given within groups corporate gover nance disclosures pages notes roche group consolidated financial statements transactions group individual members shareholders group subsidiary associated companies listing major group subsidiaries associated companies included note trans actions parent company subsidiaries subsidiaries eliminated consolidation transactions group associated companies follows income statement income sale goods supply services expenses purchase goods supply services milestone upfront payments balance sheet trade accounts receivable key management personnel members board directors roche holding ltd receive annual remuneration thousand swiss francs thousand swiss francs time expenses related membership board committees total payments nonexecutive directors remuneration expenses million swiss francs million swiss francs payments dr f humer also member executive committee included figures executive committee members executive committee received total remuneration shown table salary bonuses total cash remuneration paid options awarded pension social insurance contributions paid group supplementary information given within groups corporate governance disclosures pages cash flow statement millions chf cash flows operating activities cash flows operating activities derived groups primary activities described divisional review calculated indirect method adjusting groups operating profit operating income expenses cash flows example depreciation amortisation impairment order derive cash generated operations operating cash flows shown cash flow statement operating cash flows also include income taxes paid activities including example taxes paid gains labcorp share sales notes roche group consolidated financial statements net income add back nonoperating income expense income associated companies financial income exceptional impairment financial assets income taxes income applicable minority interests operating profit depreciation property plant equipment amortisation goodwill amortisation intangible assets impairment longterm assets changes group organisation chugai transaction writeoff fair value adjustments inventories charge vitamin case major legal cases expense defined benefit postemployment plans adjustments cash generated operations cash flows financing activities cash flows financing activities primarily proceeds issue repayments groups equity debt instruments also include interest payments dividend payments instruments cash flows shortterm financing including finance leases also included cash flows indicate groups transactions providers equity debt financing cash flows shortterm borrowings shown net movement consist large number transactions short maturity interest dividends paid interest paid dividends paid total cash flows investing activities cash flows investing activities principally arising groups investments inproperty plant equipment intangible assets acquisition divestment subsidiaries associated companies businesses cash flows connected groups portfolio marketable securities investments also included interest anddividend payments received respect securities investments cash flows indicate groups net reinvestment operating assets cash flow effects changes group organisation well cash generated groups investments cash flows marketable securities including income capital gains losses shown net movement groups portfolio consist large number positions held longterm basis cash flows labcorp transactions see note shown separate line cash flow statement cash flows respect chugai consist cash payments roche third parties less cash held chugai acquired notes roche group consolidated financial statements interest dividends received interest received dividends received total significant noncash transactions significant noncash investing financing transactions included nonvoting equity securities used disetronic acquisition see note dsm shares acquired disposal vitamins fine chemicals business see note nonvoting equity securities used conversion helveticus bonds see note subsequent events artus january group acquired interest artus gmbh artus million swiss francs million swiss francs paid december additional paid capital artus german biotechnology company develops products detection pathogens group right appoint two six members supervisory board artus accordingly artus reported associated company igen january igen received clearance relevant regulatory authorities called extraordinary general meeting february approve acquisition igenby group approved igen shareholders would receive usd per share one share bioveris stock new public company spunoff igen connection proposed acquisition igen group contribute million us dollars igen would transferred bioveris would purchase igens shares million us dollars giving total cashoutflow million us dollars see also note notes roche group consolidated financial statements subsidiaries associated companies listed companies share capital country companies city currency millions switzerland roche holding ltd basel chf stock exchange zurich valor share valor genussscheine isin share ch isin genussscheine ch market capitalisation chf usa cidgenentech inc south san francisco usd stock exchange new york incorporated isin us delaware share market capitalisation usd usa cidtripath imaging inc burlington usd stock exchange nasdaq national isin us share market capitalisation usd japan cidchugai pharmaceutical co ltd tokyo jpy stock exchange tokyo isin jp share market capitalisation jpy canada cid isotechnika inc edmonton cad stock exchange toronto isin ca share market capitalisation cad great britain cidantisoma plc london gbp stock exchange london isin gb share market capitalisation gbp non listed companies share capital country companies city currency millions argentina productos roche sa qumica e industrial buenos aires ars australia roche diagnostics australia pty limited castle hill aud roche products pty limited dee aud syntex australia limited north sydney aud austria roche austria gmbh vienna eur roche diagnostics gmbh vienna eur bangladesh roche bangladesh ltd dhaka bdt belgium nv roche sa brussels eur roche diagnostics belgium sa brussels eur bermuda canadian pharmholding ltd hamilton usd corange international ltd hamilton usd corange ltd hamilton usd roche capital management ltd hamilton usd roche capital transactions limited hamilton usd roche financial products limited hamilton usd roche financial services ltd hamilton usd roche healthcare limited hamilton usd roche international finance bermuda ltd hamilton usd roche international ltd hamilton usd roche intertrade ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd brazil produtos roche qumicos e farmacuticos sa paulo brl roche diagnostics brasil ltda paulo brl notes roche group consolidated financial statements share capital country companies city currency millions canada chempharm limited toronto cad hoffmannla roche limited toronto cad roche diagnostics ltd quebec cad sapac corporation ltd st john chile productos roche ltda santiago de chile clp china roche diagnostics hong kong limited hong kong hkd roche diagnostics shanghai limited shanghai usd roche hong kong limited hong kong hkd roche shanghai management co ltd shanghai usd cid shanghai roche pharmaceuticals limited shanghai usd colombia productos roche sa bogot cop costa rica productos roche sa san jos usd roche servicios sa san jos usd czech republic roche sro prague czk denmark roche hvidovre dkk dominican republic productos roche dominicana sa santo domingo dop ecuador roche ecuador sa quito usd egypt roche egypt sae giza egp ropharm limited giza egp el salvador productos roche el salvador sa san salvador usd finland roche oy espoo eur france hoffmannla roche france sas neuillysurseine eur laboratoires roche nicholas sas gaillard eur roche diagnostics sa meylan eur roche sa neuillysurseine eur germany consulab mannheim gmbh mannheim eur corange deutschland holding gmbh mannheim eur disetronic medical systems gmbh sulzbach eur galenus mannheim gmbh mannheim eur hestia health care gmbh mannheim eur hoffmannla roche aktiengesellschaft grenzachwyhlen eur roche consumer health deutschland gmbh eppstein eur roche deutschland holding gmbh grenzachwyhlen dem roche diagnostics gmbh mannheim eur great britain roche diagnostics ltd lewes gbp roche holding uk limited welwyn garden city gbp roche products limited welwyn garden city gbp roche registration limited welwyn garden city gbp greece roche hellas sa athens eur guatemala productos roche guatemala sa guatemala city gtq guernsey disetronic finance jersey ltd st peter port chf roche capital market international limited st peter port chf roche financial market limited st peter port chf roche international finance corporation limited st peter port chf honduras productos roche honduras sa tegucigalpa hnl hungary roche hungary ltd budapest huf india roche diagnostics india pvt ltd mumbai inr roche scientific company india private limited mumbai inr indonesia pt roche indonesia jakarta idr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur italy roche diagnostics spa milan eur roche spa milan eur japan roche diagnostics kk tokyo jpy luxembourg pharminvest sa luxembourg eur malaysia roche diagnostics malaysia sdn bhd kuala lumpur myr roche malaysia sdn bhd kuala lumpur myr mexico grupo roche syntex de mxico sa de cv mexico city mxn lakeside de mxico sa de cv mexico city mxn productos roche sa de cv mexico city mxn syntex sa de cv mexico city mxn morocco roche immobilire maroc sarl casablanca mad cid roche sa casablanca mad notes roche group consolidated financial statementsshare capital country companies city currency millions netherlands disetronic medical systems bv vianen eur roche diagnostics nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholding bv woerden eur new zealand roche diagnostics new zealand pty ltd auckland nzd roche products new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio norway roche norge oslo nok pakistan roche pakistan ltd karachi pkr panama productos roche interamericana sa panama city usd productos roche panam sa panama city pab roche capital corporation panama city roche financial management inc panama city chf syntex corporation panama city usd peru productos roche qumica farmacutica sa lima pen philippines roche philippines inc makati php poland roche diagnostics polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda lindaavelha eur puerto rico syntex puerto rico inc humacao usd russia roche moscow ltd moscow rub singapore boehringer mannheim far east pte ltd singapore sgd roche diagnostics asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd south africa roche products proprietary limited johannesburg zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw spain andreu roche sa madrid eur boehringer mannheim roche sa madrid eur roche diagnostics sl barcelona eur roche farma sa madrid eur syntex roche sa madrid eur sweden disetronic medical systems ab nacka strand sek roche ab stockholm sek roche diagnostics scandinavia ab bromma sek switzerland disetronic handels ag burgdorf chf disetronic holding ag burgdorf chf disetronic licensing ag burgdorf chf disetronic medical systems ag burgdorf chf f hoffmannla roche ltd basel chf imib insitute medical informatics biostatistics ltd basel chf pharmexbio ltd zug chf roche consumer health ltd kaiseraugst chf roche diagnostics schweiz ltd rotkreuz chf roche diagnostics international ltd steinhausen chf roche finanz ag basel chf roche instrument center ltd rotkreuz chf roche kapitalmarkt ag basel chf roche pharma switzerland ltd reinach chf roche treasury management europe ltd basel chf syntex corporation basel chf valorfides ag chur chf cid basilea pharmaceutica ltd basel chf cid rabbitair ltd zurichkloten chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostics thailand limited bangkok thb roche thailand limited bangkok thb turkey roche diagnostik sistemleri ticaret istanbul trl roche mstahzarlari sanayi anonim sirketi istanbul trl uruguay roche international ltd montevideo sapac corporation ltd montevideo notes roche group consolidated financial statements share capital country companies city currency millions usa american roche international inc little falls cad disetronic medical systems inc st paul usd hoffmannla roche inc nutley usd roche carolina inc florence roche colorado corporation boulder usd roche diagnostics corporation indianapolis usd roche holdings inc wilmington usd roche laboratories inc nutley roche molecular systems inc pleasanton roche palo alto llc palo alto usd cidbayer roche llc morristown usd venezuela productos roche sa caracas veb group holds interest companies listed exceptions marked follows cid group companies group interest fully consolidated cid joint venture group interest method proportionate consolidation cid associated companies group interest equity method consolidation share capital shown millions local currency share capital less local currency units notes roche group consolidated financial statementsreport group auditors general meeting roche holding ltd basel auditors group audited roche group consolidated financial statements consolidated income statement consolidated balance sheet consolidated statement changes equity consolidated cash flow statement consolidated notes pages year ended december consolidated financial statements responsibility board directors roche holding ltd responsibility express opinion consolidated financial state ments based audit confirm meet swiss legal requirements concerning professional qualification independence audit conducted accordance auditing standards promulgated swiss pro fession international standards auditing require audit planned performed obtain reasonable assurance whether consolidated financial state ments free material misstatement examined test basis evidence support ing amounts disclosures consolidated financial statements also assessed accounting principles used significant estimates made overall consolidated financial statement presentation believe audit provides reasonable basis opinion opinion consolidated financial statements roche group present fairly material respects financial position december results operations cash flows year ended accordance international financial reporting standards ifrs comply swiss law recommend consolidated financial statements submitted approved pricewaterhousecoopers ag clive aj bellingham dr matthias jeger basel february report group auditors multiyear overview statistics reported statement income millions chf sales ebitda operating profit net income research development balance sheet millions chf longterm assets current assets total assets equity minority interests noncurrent liabilities current liabilities additions property plant equipment personnel number employees end year key ratios net income sales net income equity research development sales current ratio equity minority interests total assets sales per employee thousands chf data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf b cash warrants addition dividend adjusted chf cash warrants addition dividend unadjusted chf information table stated reported changes accounting policy arising changes international financial reporting standards andthe stock split arenot applied retrospectively warrants held final exercise date b addition normal dividend shareholders approved share nonvoting equity security special ro centenary warrant worth chf date issue holders option cash equivalent chf c net income related key ratios shown special charges million swiss francs net tax incurred following corange acquisition include corange respect balance sheet data multiyear overview c g h e f e f warrants held final exercise date e dividend include special dividend relating spinoff fragrances flavours division f dividend proposed board directors g sales reduced million swiss francs due reclassification cash discounts see note consolidated financial statements h ebitda restated format used financial statements ie exceptional items multiyear overview sales division millions chf pharmaceuticals diagnostics vitamins fine chemicals fragrances flavours total sales geographical area millions chf switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania total sales reduced million swiss francs due reclassification cash discounts see note consolidated financial statements multiyear overviewadditions property plant equipment division millions chf pharmaceuticals diagnostics vitamins fine chemicals fragrances flavours others total additions property plant equipment geographical area millions chf switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania total multiyear overview roche securities share price performance chf roche share adjusted swiss market index rebased nonvoting equity security genussschein price performance chf roche nonvoting equity security adjusted swiss market index rebased american depositary receipt adr price performance usd roche adr adjusted sp index rebased one roche american depositary receipt adr equivalent one nonvoting equity security genussschein adrs traded united states overthecounter market since july roche securitiesnumber shares nonvoting equity securitiesa number shares nominal value chf chf number nonvoting equity securities genussscheineno nominal value total data per share nonvoting equity securityin chf net income c equity dividend e stock price shareb high low yearend stock price nonvoting high equity security low genussscheinb yearend historic stock price unadjusted shares yearend nonvoting equity securities genussschein yearend market capitalisation millions chf yearend c key ratios yearend net income equity dividend yield shares dividend yield nonvoting equity securities genussscheinein priceearnings shares priceearnings nonvoting equity securities genussscheine nonvoting equity security genussscheinconfers rights shares participate avail able earnings remaining proceeds liquidation following repayment nominal value shares participation certificate capital shares nonvoting equity securities listed swiss exchange roche holding ltd restrictions ownership shares nonvoting equity securities b stock price data reflect daily closing prices stock price figures prior june adjusted effects givaudan spinoff adjustment factors used shares nonvoting equity securities factors used independent financial institutions c net income per share market capitalisation figures assume equity instruments held outstanding dividend include special dividend relating spinoff fragrances flavours division e dividend proposed board directors ticker symbols share nonvoting american equity security depositary receipt reuters roczs roczgs rhhbypk bloomberg ro sw rog sw rhhby us swx swiss exchange ro rog roche securities roche holding ltd basel financial statements income statement millions chf income income participations interest income loans group companies interest investment income income total income expenses financial expenses administration expenses loss disposal participations depreciation participations expenses total expenses profit year taxes taxes net profit year financial statementsbalance sheet december millions chf longterm assets participations loans group companies total longterm assets current assets accounts receivable group companies accounts receivable prepaid expenses accrued income marketable securities liquid funds total current assets total assets equity share capital nonvoting equity securities genussscheine pm pm general legal reserve free reserve special reserve available earnings balance brought forward previous year net profit year total equity noncurrent liabilities provisions loans group companies total noncurrent liabilities current liabilities accounts payable group companies liabilities accrued liabilities total current liabilities total liabilities total equity liabilities pm pro memoria nonvoting equity securities nominal value financial statements notes financial statements general financial statements roche holding ltd basel prepared accordance provisions swiss company law accepted business principles valuation methods translation foreign currencies balance sheet assets liabilities disclosed net realisable values exceptions tothis rule participations shown acquisition values less appropriate writedowns marketable securities shown lower cost market value unrealised foreign currency gains balance sheet items deferred expenses income aswell foreign currency transactions translated exchange rates ruling relevant transaction dates details specific items income total income million swiss francs million swiss francs higher previous year mainly due higher dividend income taxes tax charge includes corporate income capital taxes withholding taxes stamp duty equity total equity equals previous year total assets change previous year due disetronic acquisition increasing participations loans group companies movements equity shown table millions swiss francs general share legal free special available total capital reserve reserve reserve earnings equity january net income dividends paid transfer free reserve december net income dividends paid transfer free reserve december net income dividends paid transfer free reserve december notes financial statementsshare capital previous year share capital amounts million swiss francs share capital consists bearer shares nominal value swiss franc included equity nonvoting equity securities genussscheine part share capital confer voting rights however nonvoting equity security genussschein confer rights one shares participate available earnings inany remaining proceeds liquidation following repayment theshare capital guarantees guarantees favour group companies total million swiss francs previous year mil lion swiss francs time preparing balance sheet risks arising contingent liabilities discernible convertibles options reference made notes consolidated financial statements equity instruments reference made notes consolidated financial statements pledged assets assets total book value million swiss francs previous year pledged security companys commitments participations major participations listed pages important shareholders shares company bearer shares reason company notkeep aregister shareholders following figures based information shareholders theshareholder validation check annual general meeting april onother information available company previous year shares shareholders group pooled voting rights comprising dr lukas hoffmann ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri ms beatrice oeri msmaja oeri dr fritz gerbera previous year shares participation novartis international ltd basel including affiliates thereofb information supplied shareholders figure shares include shares without pooled voting rights held outside group individual members group b figures december supplied novartis international ltd basel notes financial statements appropriation available earnings proposals general meeting chf available earnings net profit year balance brought forward previous year total available earnings appropriation available earnings distribution ordinary dividend chf gross per share nonvoting equity securitygenussschein chf last year transfer free reserve total appropriation available earnings carried forward account appropriation available earningsreport statutory auditors general meeting roche holding ltd basel statutory auditors audited accounting records financial statements income statement balance sheet notes pages roche holding ltd basel fortheyear ended december financial statements responsibility board directors responsibility toexpress opinion financial statements based audit confirm meet legal requirements concerning professional qualification independence audit conducted accordance auditing standards promulgated swiss profession require audit planned performed manner obtain reasonable assurance whether financial statements free material mis statement examined test basis evidence supporting amounts disclosures inthefinancial statements also assessed accounting principles used significant estimates made overall financial statement presentation believe audit pro vides areasonable basis opinion opinion accounting records financial statements proposed appropriation available earnings comply swiss law companys articles incorporation recommend financial statements submitted approved ernst young ltd conrad lffel jrg zrcher basel february report statutory auditors arctic circle tropic cancer tropic capricorn roche ct ia rcrc letic global market presence sales switzerland manufacturing argentina research development australia toe lr lv mic ae ns u f fi ca tn uc rii nn gg third parties austria bangladesh belgium bermuda brazil canada chile china colombia costa rica czech republic denmark dominican republic ecuador egypt el salvador finland france germany great britain greece guatemala roche global market presence arctic circle tropic cancer tropic capricorn cnt ia rcrc letic guernsey south africa honduras south korea hungary spain india sweden indonesia taiwan ireland thailand italy turkey japan uruguay luxembourg usa malaysia venezuela mexico morocco netherlands new zealand nicaragua norway pakistan panama peru philippines poland portugal puerto rico russia singapore roche global market presence cautionary statement regarding forwardlooking statements annual report contains certain forward opments economic conditions delay looking statements forwardlooking inability obtaining regulatory approvals bring statements may identified bywords ing products market fluctuations currency believes expects anticipates projects intends exchange rates general financial market seeks estimates future similar conditions uncertainties discovery devel expressions discussion among opment marketing new products new uses things strategy goals plans intentions various existing products increased government factors may cause actual results differ materially pricing pressures interruptions production future reflected forwardlook loss inability obtain adequate protection ing statements contained annual report intellectual property rights litigation among others pricing product initiatives loss key executives orother employees ofcompetitors legislative regulatory devel adverse publicity news coverage published f hoffmannla roche ltd basel switzerland tel fax media office corporate communications basel switzerland tel fax investor relations basel switzerland tel fax world wide web httpwwwrochecom order tel fax publications email baselwebmasterrochecom next annual general meeting april trademarks mentioned enjoy legal protection roche annual report published german original language english roche annual report issued f hoffmannla roche ltd basel corporate communications design wirz corporate ag zurich source associates ag zurich photos mike frei zurich roche corporate photolibrary basel typesetting staufferfebel ag basel lithos lithoteam ag allschwilbasel printers birkhusergbc ag reinachbasel binding buchbinderei grollimund ag reinachbasel cover urogenital diseases ureanaclalbumin crystal polarising microscopydiagnostics sales division pharmaceuticals asia latin america sales region north america europe others others diagnostics employees division pharmaceuticals latin america asia north america employees region others europe continuing businesses